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RESUMO 
A doença de Huntington (HD, do inglês „Huntington’s disease’) é uma doença 
neurodegenerativa autossómica dominante, caracterizada por perda selectiva dos neurónios 
estriatais. É marcada por movimentos corporais involuntários (coreia), discurso “arrastado”, 
dificuldades em engolir, distúrbios emocionais e demência. A HD é causada por uma 
mutação (expansão de CAGs) no gene IT15 (ou gene HD), que codifica para a proteína 
huntingtina (Htt). Nos doentes de HD, a Htt mutante (mHtt) apresenta um elevado número 
de poliglutaminas no seu terminal amínico. De entre vários mecanismos celulares, a mHtt 
interfere com o sistema ubiquitina-proteassoma, mecanismos apoptóticos, autofagia, 
transcrição e homeostase mitocondrial. Recentemente foi demonstrado pelo nosso grupo 
que a actividade e expressão da enzima piruvato desidrogenase (PDH) estão diminuídas em 
cíbridos citoplasmáticos de HD, resultando em alterações bioenergéticas nessas células. 
Actualmente, não existe um tratamento para esta doença devastadora. No entanto, 
evidências anteriores sugerem que a insulina e o insulin-like growth factor-1 (IGF-1) 
podem actuar como potenciais agentes protectores na HD. Assim, colocámos a hipótese de 
que ambos os factores neurotróficos poderiam prevenir ou atenuar as alterações 
bioenergéticas após expressão da mHtt completa (full-length). Para além disso, os 
inibidores das desacetilases de histonas (iHDACs) podem também ser usados para reverter 
a disfunção associada à HD, melhorando o processo transcricional alterado após expressão 
de mHtt. Assim, neste trabalho utilizámos uma linha de células estriatais derivadas de 
ratinhos (murganhos) knock-in homozigóticos que expressam mHtt com 111 glutaminas 
(STHdh
Q111/Q111
) versus células estriatais obtidas de ratinhos wild-type (que expressam Htt 
com 7 glutaminas) tratadas com insulina, IGF-1, e os iHDACs tricostatina A (TSA), 
butirato de sódio (SB) e 4-fenilbutirato (PB). Por fim, de modo a estudar o papel da 
mitocôndria em células humanas que expressam mHtt produziram-se células rho-zero a 
partir de linfoblastos humanos. 
Os nossos resultados mostraram que, em comparação com células wild-type, as células 
estriatais STHdh
Q111/Q111
 apresentaram maior produção de espécies reactivas de oxigénio 
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(ROS), maior fosforilação/inactivação da PDH e diminuição da actividade da PDH e dos 
níveis da sua subunidade E1alpha, o que poderá contribuir para a diminuição da viabilidade 
celular (por aumento da apoptose e necrose). Para além disso, as células STHdh
Q111/Q111
 
exibiram algumas alterações bioenergéticas, incluindo a diminuição dos rácios ATP/ADP e 
lactato/piruvato, da actividade da enzima lactato desidrogenase (LDH) e um aumento dos 
níveis de fosfocreatina (PCr) e piruvato. Por outro lado, a exposição das células ao 
dicloroacetato, um activador indirecto da PDH, diminuiu a produção de ROS em células 
STHdh
Q111/Q111
. A pré-incubação com insulina e IGF-1 não afectou significativamente as 
alterações bioenergéticas acima referidas. Contudo, observámos um efeito promissor de 
IGF-1 (1 nM) no restabelecimento da actividade da LDH, assim como uma ligeira 
diminuição dos níveis de piruvato. Adicionalmente, mostrámos que os iHDACs podem ter 
efeitos protectores na HD, diminuindo a morte celular por apoptose nas células 
STHdh
Q111/Q111
 e, consequentemente, aumentando o número de células viáveis. Ainda, a 
exposição a SB (500 μM) diminuiu a fosforilação da PDH e aumentou os níveis da sua 
subunidade E1alpha nas células STHdh
Q111/Q111
.  
Por fim, produzimos células rho-zero após tratamento com baixas concentrações de 
brometo de etídio, durante 27 dias. Porém, o processo de criação de células rho-zero 
pareceu ser dependente do tipo de linha celular. Assim, serão necessários estudos futuros de 
forma a definir um protocolo exacto para a criação de células rho-zero a partir de linhas 
celulares linfoblastóides. A maior limitação parece ser a rapidez com que se observa a 
repopulação mitocondrial, o que poderá trazer algumas dificuldades à manutenção do 
estadio rho-zero. 
Em conclusão, os dados apresentados neste estudo descrevem alguns défices mitocondriais 
presentes nas células STHdh
Q111/Q111
, enfatizando a PDH como um importante alvo 
terapêutico. Adicionalmente, demonstrámos que, no modelo celular testado, os iHDACs 
(em particular o SB), podem prevenir estes défices de forma mais eficaz comparativamente 
aos efeitos mediados pela insulina ou IGF-1. Assim, os iHDAC representam uma estratégia 
terapêutica promissora na HD. 
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ABSTRACT 
Huntington‟s disease (HD) is an autosomal dominant neurodegenerative disease, 
characterized by selective neuronal loss of striatal and cortical neurons. It is marked by 
involuntary body movements (e.g. chorea), slurred speech, difficulties in swallowing, 
emotional disturbances and dementia. HD is caused by a mutation (CAG expansion) in the 
IT15 (or HD) gene, which encodes the protein huntingtin (Htt). In HD patients, mutant Htt 
(mHtt) presents an increased number of polyglutamines in its N-terminal. Among other 
pathways, mHtt interferes with the ubiquitin-proteasome system (UPS), apoptotic 
mechanisms, autophagy, transcription and mitochondrial homeostasis. Recent studies from 
our group have shown that pyruvate dehydrogenase (PDH) activity and expression were 
decreased in HD cytoplasmic hybrids (cybrids), resulting in changes in mitochondrial 
bioenergetics in these cells. Currently, there is no effective treatment for this devastating 
disease. However, previous evidence suggests that insulin, insulin-like growth factor-1 
(IGF-1) and also histone deacetylase inhibitors (iHDACs) may offer potential therapeutic 
protection against HD. Thus, the aim of this work was to analyze the levels of several 
energy metabolic parameters and to evaluate the protective effect of both IGF-1 and insulin 
in these parameters; and, also, to investigate the influence of iHDACs (trichostatin A (TSA), 
sodium butyrate (SB) and 4-phenylbutyrate (PB)), on PDH protein expression and 
regulation. For this purpose, we used striatal STHdh
Q111/Q111
 cell line derived from HD 
knock-in mice expressing mHtt with 111 glutamines versus striatal cells from wild-type 
mice (expressing Htt with 7 glutamines) treated with insulin, IGF-1 and the iHDACs. In 
addition, in order to study the role of mitochondrial dysfunction in HD, we produced rho-
zero cells from HD patients‟ and control lymphoblasts.  
Our results showed that, in comparison with wild type cells, striatal STHdh
Q111/Q111 
cells 
produced high levels of reactive oxygen species (ROS), increased PDH 
phosphorylation/inactivation, and decreased PDH activity and E1alpha protein levels, 
which could contribute for lower cell viability, as a result of increased apoptosis and 
necrosis. Also, STHdh
Q111/Q111
 cells showed a decrease in ATP/ADP ratio and lactate 
dehydrogenase (LDH) activity and increased phosphocreatine (PCr) levels. Moreover, 
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pyruvate levels were increased in mutant cells whereas lactate levels were unchanged. 
Insulin (0.1 nM) and IGF-1 (1 nM) treatment significantly decreased PCr levels, whereas 
IGF-1 (1 nM) also decreased pyruvate levels and LDH activity in mutant cells, when 
compared to wild-type cells. Also, exposure to dicloroacetate, an indirect activator of PDH, 
decreased ROS production in STHdh
Q111/Q111
 cells. Additionally, we showed that iHDACs 
can have protective effects in HD, by decreasing cell death by apoptosis in STHdh
Q111/Q111
 
cells, thereby increasing the number of viable cells. In the presence of SB (500 μM), PDH 
E1alpha subunit levels increased and PDH phosphorylation decreased in STHdh
Q111/Q111
 
cells.  
Also, we were able to produce rho-zero lymphoblast cells using ethidium bromide, for 27 
days. Nevertheless, the production of rho-zero cells seemed to be dependent on the cell line. 
Thus, further studies will be needed in order to define a precise protocol to create a rho-
zero status from lymphoblastoid cell lines. The main limitation seems to be a rapid 
mitochondrial repopulation, which presents some concerns to the maintenance of rho-zero 
lines. 
Data presented in this study describe some mitochondrial deficits present in HD striatal 
cells, emphasizing PDH as an interesting therapeutic target. Also, we show that, in this cell 
model, iHDACs (and particularly SB) more efficiently prevented the observed 
mitochondrial deficits compared to both insulin or IGF-1. Therefore, iHDACs represent a 
promising therapeutic strategy in HD.   
 
 
Key words: Huntington‟s disease, pyruvate dehydrogenase, HDAC inhibitors, insulin, rho-
zero cells. 
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1.1. HUNTINGTON‟S DISEASE 
Neurodegenerative disorders are a common form of neurological disorders, characterized 
by a progressive loss of neurons, in selective areas of the central nervous system, and 
protein aggregation, that lead to neurological deficits (Lee and Kim, 2006a). Huntington‟s 
disease (HD) is a debilitating neurodegenerative disorder that affects 3-10 in 100,000 
individuals, mainly Caucasians (Gil and Rego, 2008). HD is a late onset disease occurring 
mostly in people around 40 years of age; however its symptoms may appear in an age range 
of 8-83, with average survival of about 20 years after the onset (Mahant et al., 2003; 
Paulsen et al., 2005). HD is characterized by uncontrolled movements (chorea, dyskinesia 
and dystonia), abnormal balance when walking, slurred speech, difficulty in swallowing, 
thinking difficulties, emotional disturbances and dementia (Harper, 1991; Paulsen, 1999). 
These symptoms are related with the selective loss of neurons in the striatum (caudate and 
putamen nuclei) that extend to other brain areas during late stages of the disease (Gil and 
Rego, 2008). 
HD is an autosomal-dominant inherited neurodegenerative disorder which was first 
described in 1872 by George Huntington, a physician from Pompery (Ohio) (Lee and Kim, 
2006a). Nevertheless, the molecular/genetic basis of the disease only started to be 
understood almost one century after that date (Lee and Kim, 2006b; Eskenazi et al., 2007). 
HD is caused by a genetic alteration on chromosome four (4p16.3), in the gene first called 
IT15 (interesting transcript 15) or HD gene (Albin and Tagle, 1995). The HD mutation 
consists in an expansion of CAG repeats within the coding region of the HD gene (exon 1), 
that encodes for the protein huntingtin (Htt). Htt is a widely expressed protein, with about 
350 kDa (3144 amino acids) and the HD mutation leads to a tail of polyglutamines (polyQ) 
located in its N-terminal (Albin and Tagle, 1995; Gil and Rego, 2008). Studies in HD and 
control patients showed that the normal gene exhibits 9-39 CAG repeats in the HD gene 
(mean 18-19) whereas the mutant gene shows repeat lengths of 36-121 (mean 42-46). 
Asymptomatic patients that exhibit repeat lengths of 40 develop HD, while repeats of 30 or 
less make HD development unlikely (Albin and Tagle, 1995). Also, the length of the polyQ 
repeats increases in every generation when inherited from the father, by a phenomenon 
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named genetic anticipation. More than 60 CAGs repeats are related with the juvenile-onset 
disease, and the age of onset is thought to be inversely correlated with the length of the 
CAG repeat (Reddy et al., 1999; Nance and Myers, 2001). However, there are other genes 
that may influence the age of onset of the disease, such as the chromosome loci 18q22 and 
6q23-24 that were identified by genotyping. Nevertheless, further studies must be done to 
completely understand the molecular consequences/determinants of these genes (Li et al., 
2006). 
The severity of the disease can be graded by a system developed by Vonsattel et al. (1983) 
that defines 5 grades (0-4) and is based on the pattern of striatal degeneration in post-
mortem tissues (Figure 1). In grade 0 patients, the brain is apparently normal, but upon 
histological examination some neuronal loss can be detected; atrophy in the tail (and maybe 
in the body) of the caudate nucleus is seen in grade 1 patients; grade 2 patients display 
more pronounced striatal atrophy than grade 1; grade 3 is associated with gross striatal 
atrophy; and grade 4 includes the cases of severe atrophy of the striatum with up to 95% 
neuronal loss (Vonsattel et al., 1985). The severity of symptoms also changes with the 
course of the disease, starting with subtle manifestations: clumsiness, difficulties with 
smooth eye pursuit and slight uncontrolled and awkward movements. Then, the muscular 
involuntary movements become more severe as the patients lose their capacity to move or 
communicate (Gil and Rego, 2008). Bradykinesia and rigidity also appear in late stages or 
juvenile cases of the disease (García Ruiz et al., 2002), and death commonly occurs by 
heart failure or aspiration pneumonia (Chiu and Alexander, 1982). Also, HD patients are 
characterized by profound weight loss, independently of their caloric intake (Djoussé et al., 
2002), suggesting some abnormalities in energy production. In juvenile HD there are 
different symptoms, like absence of chorea (in some cases) and epileptic seizures (van Dijk 
et al., 1986). 
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Figure 1 – Evolution of Huntington’s disease over time. Selective dysfunction and death of striatal and (to lesser extent) 
cerebral cortical neurons. HD subjects were grouped according to disease stage. The color scale at the bottom represents 
differences in brain thickness, with red to yellow indicating regions of more significant thinning in HD, compared to age 
matched controls. The magnitude of the brain thickness change is displayed as well, transitioning from red (5% loss) to 
yellow (>20% loss) (Rosas et al., 2008). 
 
It is interesting to note that the degree of striatal atrophy is related with the deterioration of 
nonstriatal brain structures. For example, in grades 3 and 4 there are other areas affected 
besides the striatum (cerebral cortex, globus pallidus, thalamus, subthalamic nucleus, 
substantia nigra, white matter and cerebellum), while in grades 1 and 2 nonstriatal areas 
only show a slight atrophy (Vonsattel, 1998). Also, the hypothalamus was shown to be 
significantly atrophied in HD patients because of the loss of somatostatin-positive neurons 
in the lateral tuberal nucleus, and of orexin/hypocretin-secreting neurons in lateral 
hypothalamus (Gil and Rego, 2008). In the striatum, medium-sized spiny neurons are the 
most affected neuronal population, as they correspond to about 95% of the striatal 
population of neurons. These neurons are in part regulated by dopaminergic inputs 
emanating from the substantia nigra pars compacta in the brain stem, and by glutamatergic 
inputs from the cerebral cortex and thalamus. They project back to the basal ganglia output 
nuclei via a direct and an indirect pathway, which cross the external segment of the globus 
pallidus and the subthalamic nucleus. Medium-sized spiny neurons use mostly the 
inhibitory transmitter γ-aminobutyric acid (GABA) and dynorphin, enkephalin or substance 
P as co-transmitters. Interestingly, the striatal projections of the direct and indirect 
pathways differ in terms of the co-transmitter used and the type of dopamine (DA) receptor 
that is preferentially expressed. Thus, neurons of the direct pathway contain substance P 
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and preferentially express excitatory D1 DA receptors, whereas neurons of the indirect 
pathway contain enkephalin and preferentially express inhibitory D2 DA receptors. The 
indirect pathway is the first to be affected, then, along disease progression, both pathways 
are affected. The loss of the inhibitory effect of the medium-sized spiny neurons is believed 
to be responsible for the uncontrolled movements observed in HD patients (Gil and Rego, 
2008). 
The presence of neuronal intranuclear inclusions (NIIs) and protein aggregates in 
dystrophic neuritis in striatal and cortical neurons is another characteristic of HD and 
several other polyQ expansion diseases. Interestingly, in juvenile cases there is an increase 
in the frequency of cortical neurons bearing NIIs, while striatal aggregates are practically 
absent. Also, the number of cortical inclusions correlates well with the length of the CAG 
repeat expansion and the age of disease at onset (Gil and Rego, 2008). However, the role of 
these aggregates remains unclear, with both protective (Kuemmerle et al., 1999) and toxic 
(Bates, 2003) functions described. 
Recently, Sassone et al. reported that in HD patients, in addition to neurological symptoms, 
there are some pathological phenotypes in peripheral tissues, for example, weight loss, 
muscle wasting and abnormal homeostasis (Sassone et al., 2009). This suggests that mHtt 
has an important role in the entire organism. 
1.1.1.Huntingtin 
Before 1993, there were several mechanisms suggested as participants in the pathogenesis 
of HD, based on chemical lesion studies in experimental animals. These models included 
N-methyl-D-aspartate (NMDA)-receptor-mediated glutamate excitotoxicity induced with 
quinolinic acid (NMDA receptor agonist), free radical damage and deficits in mitochondrial 
energy production induced by 3-nitropropionic acid (complex II inhibitor). After 1993, the 
year of the IT15 gene discovery, investigators concluded that the cause of HD did not fit in 
any of these categories. HD was found to be caused by an alteration in a protein named Htt 
(Gusella and MacDonald, 1998). Htt is composed of more than 3100 amino acids, and does 
not show structural homology with any other proteins (Gil and Rego, 2008). Htt is 
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predicted to consist mainly of repeated units of about 50 amino acids, termed HEAT (Htt, 
elongation factor 3, A subunit of protein phosphatase 2A, TOR1) repeats. These repeats are 
composed of two antiparallel alpha-helices with a helical hairpin configuration, which 
assemble into a superhelical structure with a continuous hydrophobic core. Also, Htt 
undergoes extensive post-translational modifications (Figure 2) (Ross and Tabrizi, 2011), 
having a nuclear export signal (NES) in its carboxyl terminus (Xia et al., 2003), which 
suggests some nuclear function. 
 
Figure 2 – Htt domain structure and post-translational modifications. Human Htt is predominantly composed of 
HEAT repeats. A polyglutamine (polyQ) stretch is located at the N-terminus. Proteolytic cleavage (by caspase 6 and other 
proteases) forms toxic N-terminal fragments, examples of which are shown (cp-1 and cp-2). The exact size of these 
fragments and the relevant cleavage enzymes are currently unknown. Many post-translational modifications (e.g., 
acetylation [Ac], phosphorylation [P], and addition of small ubiquitin-like modifiers [SUMO]) can alter Htt‟s cell biology 
and toxic effects. IVLD and NLPR are amino acid cleavage sequences. NES means nuclear export signal. Adapted  from 
Ross and Tabrizi (2011) (Ross and Tabrizi, 2011). 
 
The wild-type Htt is widely expressed throughout the body (Gil and Rego, 2008) and 
previous studies showed that knock out (KO) of the mouse HD homolog Hdh leads to 
embryonic lethality (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). However, 
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human mHtt can rescue this lethal phenotype (Leavitt et al., 2001), suggesting that Htt‟s 
function during embryonic development is independent of the length of the polyQ tail (Gil 
and Rego, 2008). Regarding its cellular location, the wild-type protein can be detected in 
the cytoplasm, associated with organelles (mitochondria, Golgi apparatus, synaptic vesicles, 
and components of the cytoskeleton), or in the nucleus (in a lesser extent) (Gil and Rego, 
2008). Htt is known to interact with a large variety of proteins principally through its N-
terminus (Gusella and MacDonald, 1998; Gil and Rego, 2008; Ross and Tabrizi, 2011). 
Among all the proteins referenced as Htt-associated proteins, there are some relevant 
examples: Htt-associated protein 1 (HAP1), Htt-interacting protein 1 (HIP1), Htt-
interacting protein 2 (HIP2), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Htt 
yeast partners (HYPA, HYPB and HYPC) and beta-tubulin (in the microtubules) (Gil and 
Rego, 2008). HAP1 was the first protein described to interact with Htt. It has about 68 kDa 
and at least two isoforms, HAP1-A and HAP1-B, and is expressed exclusively in the brain, 
where it displays a distribution that resembles that of neuronal nitric oxide synthase. HAP1 
is localized in the neuronal cytoplasm where it is associated with membranous organelles. 
HIP1 is a human homologue of Saccharomyces cerevisiae Sla2p, highly expressed in the 
brain, and it is a transmembrane protein with a talin-like domain that has been implicated in 
the assembly of the cortical cytoskeleton, in the regulation of H
+
-ATPase abundance at the 
plasma membrane, and in endocytosis. HIP2, an E2-25kD ubiquitin-conjugating enzyme, is 
involved in the catabolism of cellular proteins, is located in the cytosol and enriched in the 
brain. GAPDH is a glycolytic enzyme and HYPs are proteins that bind to Htt‟s proline-rich 
region via their WW domains (protein interaction motifs named for their critically spaced 
tryptophan (W) residues) (Gusella and MacDonald, 1998; Gil and Rego, 2008). Also, the 
functional relationship between wild-type Htt and its interacting proteins is, in some cases, 
clearly established. For example, wild-type Htt interacts with post-synaptic density 95 
(PSD95), regulating the anchoring of NMDA and kainate (KA) receptors to the post-
synaptic membrane (Sun et al., 2001); it promotes the expression of brain-derived 
neurotrophic factor (BDNF) by interacting with the transcriptional factor complex 
repressor-element-1 silencing transcription factor (REST)/neuron-restrictive silencer factor 
(NRSF) in the cytoplasm, preventing this complex from translocating into the nucleus 
(Zuccato et al., 2003), and also promotes BDNF vesicular transport (Gauthier et al., 2004). 
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Wild-type Htt is important to promote the expression of NeuroD (a transcription factor that 
is crucial for the development of the dentate gyrus of the hippocampus) (Liu et al., 2000; 
Marcora et al., 2003); additionally, wild-type Htt appears to have pro-survival 
characteristics, preventing the activation of caspases (Rigamonti et al., 2001; Gervais et al., 
2002; Zhang et al., 2006). So, it is obvious that normal Htt is very important in maintaining 
the cellular homeostasis, having functions related to protein trafficking, vesicle transport 
and anchoring to the cytoskeleton, clathrin-mediated endocytosis, post-synaptic signaling, 
transcriptional regulation and anti-apoptotic functions (Gil and Rego, 2008). 
1.1.2.Mutant Huntingtin toxicity 
In HD patients both wild-type Htt and mHtt show similar distribution in the body, with the 
highest levels found in the brain. Currently there are two hypotheses to explain the damage 
that occurs in HD (Figure 3): i) a gain of function of the mHtt; and ii) a loss of normal Htt 
function (Cattaneo et al., 2001). According to the first hypothesis (gain of function), the 
extended CAG tail is responsible for the pathogenesis of HD. Indeed, CAG itself is toxic: 
expression of CAG alone or in the context of a small part of the Htt protein, or even in a 
protein with no relevance to HD, causes neurological symptoms in animals (Housman, 
1995). The polyQ terminus of the mHtt may be cleaved from the protein, being responsible 
for the formation of intranuclear aggregates and for the inhibition of glutamate uptake in 
vitro (Wexler et al., 1987). In favor of this theory (and against the theory of loss of normal 
Htt function) some studies showed that the deletion of one Htt allele does not result in HD 
(Housman, 1995). However, Squitieri et al. suggested that homozygotes may show a more 
severe phenotype and display more rapid progression after onset of the disease, indicating 
that wild-type Htt may have a protective activity (Squitieri et al., 2003). On the other hand, 
the theory that stands for the loss of function of normal Htt is supported by the fact that 
mHtt can recruit normal Htt into insoluble aggregates, both in vitro and in vivo, suggesting 
that the toxic effect of mHtt might lie in the sequestration of normal Htt or of its functions. 
Also, the polyQ tail can affect the interactions between Htt and its partners (described 
above), breaking the cellular homeostasis (Cattaneo et al., 2001; Gil and Rego, 2008). 
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Figure 3 – Potential mechanism of cell death in Huntington’s disease. Processing of mutant Htt would generate an 
amino-terminal fragment that translocates into the nucleus and a C-terminal portion that remains in the cytoplasm. Some 
of the full-length protein might also move into the nucleus. The generation of amino-terminal fragments would coincide 
with increased toxic activity in cells. At the same time, extension of the CAG would cause a loss of function in the mutant 
protein (A) and/or the mutant protein could act negatively on the functions of the normal one (B). Finally, loss of Htt 
function might result as a consequence of decreased protein levels and stability (Cattaneo et al., 2001). 
 
The mechanism of toxicity of mHtt has been object of study in the last few years and the 
polyQ tail has been defined as the responsible for the mechanisms of pathogenesis of HD 
(Figure 4). The polyQ tail is a transglutaminase substrate that can become cross-linked via 
isopeptide bonds and this event may enhance polyQ-mediated aggregation and toxicity in 
affected neurons. The aggregation can also occur because the polyQ repeats form polar 
zippers that then aggregate. Furthermore, the glutamine expansion destabilizes the native 
conformation of the mutant protein, increasing the probability of aggregate formation. 
Additionally, protein aggregates with similar structure to NIIs have been found in neuropil 
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of HD brains. The NIIs are neither necessary nor sufficient to initiate polyQ-mediated 
diseases but the comprehension of their formation may be important to provide clues about 
the pathogenesis of polyQ disorders. Expanded polyQ proteins may adopt energetically 
stable structures, which resist to unfolding, impairing clearance by the ubiquitin-
proteasome system (UPS). Misfolded and extended half-life proteins may interact with 
other proteins in an aberrant fashion, thereby triggering selective degeneration (Cummings 
and Zoghbi, 2000). Also, the release of polyQ-rich fragments (that have a greater tendency 
to aggregate) may contribute to cytotoxicity and, importantly, the function of the UPS may 
be compromised when fragments containing more than 35Qs fail to exit through the α-ring 
of the proteasome (Jana and Nukina, 2003; Venkatraman et al., 2004). On the other hand, 
mHtt is a substrate for one or more caspases (and also calpains) (Figure 2), leading to the 
release of shorter polyQ peptides that are more prone to aggregate and exert toxic effects 
(Wellington et al., 2000; Schilling et al., 2006). Sanchez et al. (1999) proposed that 
aggregates of polyQ repeat proteins can sequester one or more procaspases, which become 
activated and set off the apoptotic pathway (Sánchez et al., 1999). Heat-shock proteins 
(HSPs) such as HSP40 and HSP70, are also involved in the noxious effects of the mHtt 
because they can be sequestered into aggregates in vivo (Wyttenbach et al., 2000). By being 
sequestered into the aggregates, these chaperones will be eventually prevented from 
exerting their normal protective functions which, over the years, is likely to lead to an 
intracellular accumulation of misfolded proteins (Gil and Rego, 2008). Related with this 
problem, autophagy is abnormal in HD cells (Krainc, 2010; Martinez-Vicente et al., 2010; 
Wong and Cuervo, 2010), probably because of the inefficient engulfment of cytosolic 
components by autophagosomes (Martinez-Vicente et al., 2010). Finally, mHtt may also 
establish abnormal protein-protein interactions with several nuclear proteins and 
transcription factors, recruiting them into aggregates and inhibiting their transcriptional 
activity (Gil and Rego, 2008). For example, mHtt can interact with TBP (TATA-binding 
protein), CREB (cAMP response element-binding; cAMP standing for cyclic adenosine 
monophosphate) (Wyttenbach et al., 2000), specificity protein 1 (SP1) (Li et al., 2002) and 
components of the basal machinery, such as the essential subunits of RNAII complex, TBP, 
TFIIF, TAFII130 (Zhai et al., 2005).  
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Figure 4 –Model of pathogenic mechanisms in HD. Htt proteins with >35 glutamine repeats fold into β-sheet structures. 
This may be facilitated by cleavage by caspases or other proteases. Intermolecular cross-links by transglutaminases, lead 
to the accumulation of aggregates of misfolded Htt in the cytoplasm (that form soluble oligomers and larger insoluble 
oligomers).  Both monomers and small oligomers are toxic by a variety of mechanisms: 1. The mutant Huntigtin cannot 
be cleaved by the proteasome leading to accumulation of Htt aggregates and to impaired proteasome function (the level of 
other misfolded proteins may be enhanced as well). 2. Mutant Htt can interact directly with mitochondria, causing the 
dysfunction of enzyme complexes of the electron transport chain and decreased calcium buffering. 3. Evidence from 
animal models and patients supports a role for excessive glutamatergic input in HD pathogenesis but the molecular 
mechanisms are not completely clear. 4. Besides other proteins, mutant Htt can also bind directly to several transcription 
factors, sequester them into aggregates and lead to transcriptional dysfunction and histone hypomethylation. 5. 
Aggregated Htt can directly initiate pro-apoptotic signaling with activation of caspases and release of cytochrome c by 
mitochondria, followed by destruction of essential proteins for neuronal survival and ultimately cell death (Fecke et al., 
2009). 
1.2. NEUROTROPHIC FACTORS AND TRANSCRIPTIONAL 
MODULATORS 
Many compounds have been tested in the past few years in order to ameliorate the HD 
symptoms. The use of neurotrophic factors (Dudek et al., 1997) and transcriptional 
modulators (Basso, 2012) have been described as important compounds in the disease‟s 
control.  
1.2.1. Neurotrophic factors 
The maintenance of brain neurons is only possible due to the existence of a complex 
network of trophic relationships. Nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) are the most typical neutrophic factors (Hohn et al., 1990), 
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also named neurotrophins. An increasing number of neurotrophic factors have been 
associated to the maintainence of brain health. These include insulin and its relatives, 
insulin-like growth factors (IGFs) -1 and -2. Indeed, insulin-like growth factor 1 (IGF-1) 
was previously described as a prototypical neuronal-survival factor (Dudek et al., 1997). 
1.2.1.1. Insulin 
Insulin is the most important anabolic hormone identified to date. Almost all cells are 
sensitive to insulin (Fulop et al., 2003). Insulin is normally present in the brain, being 
enriched in the cortex, olfactory bulb, hippocampus, hypothalamus and amygdala (Unger et 
al., 1991). Studies with a transgenic HD mouse model that expresses a portion of the 
human Htt gene along with 140 CAG repeats have shown lower insulin gene expression in 
the pancreas, which was accompanied by a high number NIIs and low insulin levels 
(Andreassen et al., 2002). This low insulin gene expression might be due to the presence of 
the polyQ tail characteristic of HD, although the precise mechanisms leading to this are not 
yet clear.  
Insulin modulates survival, neuronal growth, protein synthesis, differentiation, migration, 
metabolism, gene expression, aggregation of the cytoskeleton and formation of synapses. 
Also, insulin regulates oligodendrocyte growth, survival and myelin production (de la 
Monte, 2009). Insulin receptor (IR) belongs to the superfamily of the tyrosine-kinase 
receptors,  similarly to the insulin-like growth factor I receptor (IGF-IR) (Fulop et al., 2003; 
de la Monte, 2009). Interestingly, these receptors can heterodimerize leading to the 
formation of insulin/IGF-I hybrid receptors (Hybrid-Rs) that bind IGF-1 with high affinity 
(Pandini et al., 2002). Insulin binding to IR activates two parallel signal transduction 
cascades, identified as the phosphatidylinositol 3-kinase (PI3K)–Akt pathway and the 
classical mitogen-activated protein kinase (MAPK) pathway (van der Heide et al., 2006). 
PI3K stimulates glucose transport and inhibits apoptosis by activating Akt/Protein kinase B 
and inhibiting glycogen synthase kinase-3β (GSK-3β) (de la Monte, 2009).  Positive 
stimulation through the PI3K/Akt pathway preserves mitochondrial membrane integrity, 
and inhibits the production of free radicals that cause mitochondrial DNA damage, 
mitochondrial dysfunction, and apoptosis (Halestrap et al., 2000). In contrast, activation of 
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the MAPK pathway has been shown to be involved in cell death modulation (van der Heide 
et al., 2006). 
Brain insulin derives from synthesis in pancreatic ß-cells, which then crosses the blood 
brain barrier (Banks et al., 1997). In addition, other authors proposed that insulin can be 
synthesized de novo in the brain, in pyramidal neurons from hippocampus, prefrontal cortex 
and entorhinal and olfactory bulb, but not in glial cells (Zhao et al., 1999).  
1.2.1.2. IGF-1 
IGF-1 is a pleiotropic hormone, with an extraordinary variety of effects on target organs, 
and is mainly produced in the liver, under the control of the pituitary growth hormone. 
However, IGF-1 can also be synthesized in the brain, although in this case the growth 
hormone does not influence its expression (Bondy and Cheng, 2004). Its transcription is 
maximal during nervous system development, but it remains expressed in several adult 
brain regions, as well as in epithelial and ependymal cells (Messier and Teutenberg, 2005). 
With aging, IGF-1 levels decrease in both plasma and brain (Sonntag et al., 1999).  
At the cellular level, IGF-1 is best described as a prosurvival factor, generally acting 
through the PI3K/Akt pathway to activate antiapoptotic cascades (de la Monte, 2009). 
However, IGF-1 also enhances nerve cell metabolism and modulates neuronal excitability, 
two properties that, together with its antiapoptotic actions, may be crucial in the ability of 
IGF-1 to protect nerve cells against insults. At the tissue level, IGF-1 stimulates vessel 
formation, regulates amyloid load, and modulates the activity of neuronal circuitries (Trejo 
et al., 2004). Based on these biological activities, it is plausible that changes in IGF-1 input 
to the brain underlie (or at least contribute to) the progression of neurodegenerative 
processes.  
1.2.2. Transcriptional modulators 
Prior studies have shown that mHtt, via its polyQ expanded repeats, can affect cellular 
function in many ways, such as alteration of gene transcription, one of the best-
characterized pathobiological events leading to HD (Basso, 2012). So, global 
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transcriptional modulators, like histone deacetylase inhibitors (iHDACs), have been seen as 
a potential therapy for this disease. 
1.2.2.1. iHDACs 
Transcription is regulated by interactions between many proteins, such as transcription 
factors and histones (H1, H2A, H2B, H3, and H4), that ultimately affect the actions of 
DNA polymerase II on individual genes. Many of these interactions, in turn, are regulated 
by covalent modifications, such as acetylation, methylation, and phosphorylation. Histone 
acetylation modulates the transcription of a subset of genes, and is determined by the 
interplay between histone acetyltransferases (HATs) and histone deacetylases (HDACs). In 
the past few years, HDACs were reported as important drug targets for the treatment of 
slow progressive neurodegenerative disorders, like HD. Indeed, HDAC inhibition has been 
suggested as a therapeutic strategy to modulate the transcriptional pathology observed in 
HD (Ferrante et al., 2003; Ryu et al., 2005; Dokmanovic et al., 2007). The 18 HDACs 
known are classified into three main groups, based on their homology to yeast proteins: 
class I (HDAC1, 2, 3, 8), class IIa (HDAC4, 5, 7, 9), class IIb (HDAC6, 10) and class IV 
(HDAC11) (Vrba et al., 2011). The class III includes sirtuins, which share homology with 
the yeast Sir2, and have an absolute requirement for NAD
+
 (Dokmanovic et al., 2007). Also, 
to date, more than 50 non-histone proteins have been identified that are substrates for 
HDACs. These substrates include proteins that have regulatory roles in cell proliferation, 
cell migration, and cell death (Dokmanovic et al., 2007). 
iHDACs can be divided into several structural classes, including hydroxamates, cyclic 
peptides, aliphatic acids, and benzamides. Trichostatin A (TSA) was the first natural 
hydroxamate discovered to inhibit HDACs (Yoshida et al., 1990), and is known to inhibit 
HDAC activity (class I and II) at nanomolar concentrations. Sodium butyrate (SB) and 4-
phenylbutyrate (PB) are aliphatic acids with relatively weak activity, acting at millimolar 
concentrations (Dokmanovic et al., 2007). SB and PB inhibit HDAC class I and class IIa 
(Xu et al., 2007). 
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1.2.3. Neuroprotective role of insulin, IGF-1 and iHDACs 
Currently, there is no treatment to prevent or delay HD onset, symptom progression or 
patients‟ death. Several studies have identified compounds that might be of therapeutic 
interest in HD, for example, insulin, IGF-1 and iHDACs (TSA, SB, PB, vorinostat, valproic 
acid, etc). 
Insulin has been reported to protect from cell death induced by serum deprivation (Hamabe 
et al., 2005) and from brain damage during ischemia (Auer, 1998). Duarte et al (2005) 
concluded that insulin prevents the increase in both apoptotic and necrotic neuronal death 
associated with oxidative damage. Moreover, the decrease in intracellular uric acid and in 
reduced glutathione/oxidized glutathione (GSH/GSSG) upon oxidative stress were largely 
prevented by treatment with insulin (Duarte et al., 2005). Also, Duarte et al. concluded that 
insulin stimulates neuronal glucose uptake and subsequent metabolism into pyruvate, 
restoring intracellular ATP levels under oxidative stress (Duarte et al., 2006). These authors 
also demonstrated that insulin is neuroprotective against oxidative stress mediated by IR- 
and/or IGF-1R-induced activation of PI3K/Akt and by inhibition of GSK-3ß signaling 
pathways, which appear to modulate the expression of proteins involved in glucose 
metabolism, antioxidant defenses and anti-apoptotic mechanisms (Duarte et al., 2008). 
Trejo and colleagues (2004) demonstrated the ability of IGF-1 in controlling neurogenesis 
in adulthood, since mice with altered IGF-1 expression showed a substantial decrease in the 
formation of new neurons (Trejo et al., 2004). In support of the neuroprotective function of 
IGF-1 is the activation of the kinase Akt. Humbert and co-workers (2002) observed that 
IGF-1 is able to prevent neuronal death induced by mHtt (Humbert et al., 2002). Moreover, 
Colin et al. (2005) observed a progressive change in the Akt signaling pathway, 
characterized by a decrease in Akt levels, in both animal models and in humans with HD 
(Colin et al., 2005), which also presented an accumulation of inactive fragments of Akt, 
probably resulting from cleavage by caspase-3 (Humbert et al., 2002). 
iHDACs have been shown to have neuroprotective effects in both in vivo and in vitro 
models of brain disorders. In cultured cortical neurons, Ryu and colleagues showed that 
treatment with TSA, SB, or vorinostat protected against glutathione depletion-induced 
oxidative stress; neuroprotection involved acetylation and activation of the DNA binding 
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activity of the transcription factor Sp1 (Ryu et al., 2003). Another study showed that class 
I/II iHDACs blocked Bax-dependent apoptosis in mouse cortical neurons, by p53-
dependent and independent mechanisms (Uo et al., 2009). Moreover, Leng and Chuang 
(2006) demonstrated that valproic acid, PB or TSA treatment protected against glutamate-
induced excitotoxicity, mediated by the NMDA receptor, in cerebellar granule cells (Leng 
and Chuang, 2006). A more recent study by Leng et al. found that, under certain 
experimental conditions, class I and II iHDACs (e.g. SB, PB and TSA) potentiated these 
neuroprotective effects against excitotoxicity, when used in conjunction with lithium, 
another mood stabilizer with a robust neuroprotective profile (Leng et al., 2008). Treatment 
with TSA suppressed ongoing neuronal photoreceptor degeneration and reduced lethality in 
transgenic Drosophila expressing mHtt (Steffan et al., 2001). Another report showed that 
neurodegeneration was sensitive to the zinc-dependent fly HDAC Rpd3, whereas genetic or 
pharmacological blockade by nicotinamide of NAD
+
-dependent class III HDAC Sir2 or 
Sirt2 was neuroprotective in a Drosophila HD model. Additional neuroprotection was 
achieved when Rpd3 and Sir2 were simultaneously inhibited (Pallos et al., 2008). These 
results suggest that, in addition to class I and II HDACs, class III HDACs are also potential 
targets in HD and other diseases, where polyQs are central to pathogenesis (Chuang et al., 
2009). Importantly, a very recent report by Jeong and colleagues showed that Htt was 
acetylated at K444 by the HAT, CBP. Enhanced K444 acetylation facilitated the trafficking 
of mHtt into autophagosomes for degradation, and reduced the neurotoxicity of mHtt both 
in primary neuronal cultures and in a C. elegans HD model (Jeong et al., 2009). Recently, 
Jia et al. found that iHDACs showing high potency for inhibiting HDAC3 were the most 
effective in reversing the expression of genes relevant to HD, including Ppp1r1b, which 
encodes DARPP-32, a marker for medium spiny striatal neurons (Jia et al., 2012). 
1.3. HD MODELS 
There are several models that can be used to study HD. These include cell (in vitro or ex-
vivo) and animal models (in vivo). Among animal models the mouse models have been 
largely explored (Kohan, 2004). 
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1.3.1. Cellular models 
1.3.1.1.  Ex-vivo human HD cell models  
Peripheral ex-vivo human cell models include lymphoblasts and fibroblasts (Kohan, 2004). 
Lymphoblasts are obtained from immortalization of human lymphocytes (Mandeville and 
Wilkinson, 1982), which may be isolated from the blood of HD patients (Mandeville and 
Wilkinson, 1982; Balasubramanyam et al., 2002). This model can be representative of the 
genetic alterations in HD patients, and blood samples are relatively easy to obtain. Also, 
lymphoblasts can be used to produce rho-zero cells, and give rise to other cellular models. 
In turn, fibroblasts can be collected from patient‟s skin (Goetz et al., 1981). Both models 
carry the mHtt and, thus, these non-neuronal cells may be useful for exploring certain 
abnormal physiological processes. However, they are unlikely to mimic the neurochemical 
alterations that occur in HD (Kohan, 2004). 
1.3.1.2.  HD cybrids 
Cytoplasmic hybrids (cybrids) have been also used as ex-vivo human HD models. They are 
created when cytoplasmic contents of two different cells are rendered coexistent within a 
single plasma membrane boundary (Khan et al., 2007). HD cybrids have been generated 
from the fusion of rho-zero neuronal-like cells (without functional mitochondria) and 
enucleated human peripheral cells retaining mitochondria, such as platelets deriving from 
HD patients or control individuals (Ferreira et al., 2011). This model is useful to study 
mitochondrial dysfunction in HD, since both brain and peripheral cells show evidence of 
mitochondrial dysfunction (Kohan, 2004; Ferreira et al., 2011), but human brain cells are 
more difficult to obtain. 
Rho-zero cells have been used as an important cell model to study the effects of the lack of 
functional mitochondria in cells. These cells can be produced by a large variety of methods. 
The most common method involves a long-term exposure to ethidium bromide (EtBr), a 
cationic and lipophilic DNA-binding agent that can selectively damage mtDNA and inhibit 
mtDNA replication and transcription, when present in low concentrations (King and Attardi, 
1989). At relatively low concentrations, EtBr inhibits mtDNA polymerase gamma (POLG) 
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but not the nuclear DNA polymerases alpha and beta, since mtDNA is more susceptible to 
the EtBr damage than nuclear DNA (as the first is not as protected as nuclear DNA). This 
leads to inhibition of the replication and transcription of mtDNA, without substantially 
affecting the nuclear DNA (Qian and Van Houten, 2010). Other methods to create these 
cells include the use of: i) dideoxynocleoside analogs (Nelson et al., 1997), i) antiviral 
nucleoside analogs that inhibit mtDNA replication (Martin et al., 1994), iii) rhodamine 6-G, 
a lipophilic dye which degrades mammalian mitochondria (Trounce and Wallace, 1996), iv) 
restriction enzymes that degrade mtDNA (Kukat et al., 2008), and v) the control of mtDNA 
replication by ectopic expression of a dominant negative DNA polymerase (POLGdn) 
under the control of an inducible promoter (Jazayeri et al., 2003). Rho-zero cells are more 
sensitive than normal cells as they lack an active electron transport chain. Therefore, they 
have special requirements in order to be maintained in culture, namely uridine and pyruvate 
media supplementation (Kukat et al., 2008). The production of rho-zero cells by the EtBr 
method can be very effective because the inhibition of mtDNA transcription leads to the 
lack of expression of mitochondrial genome-encoded proteins. However, if the agent is 
removed before complete depletion of all the mtDNA, cells can regain an active 
mitochondrial genome (Moraes et al., 1999). These cells are essential components for the 
creation of cybrids. 
The cybrid model is well accepted in the study of mitochondrial diseases, or in diseases 
where the mitochondrion may have a relevant role. Specifically, the approach is designed 
so that mtDNA residing in cytosolic mitochondria of one cell type becomes incorporated 
within the cytoplasm of the rho-zero cell (Khan et al., 2007). Cybrids can be used to study 
mtDNA mutations, genome compatibility and also to develop new therapies (Khan et al., 
2007; Swerdlow, 2007; Trimmer and Bennett, 2009). Presently, HD cybrids are used as a 
model to investigate how the mitochondria are affected in HD. These cybrids have been 
produced by fusing mitochondrial DNA-depleted human teratocarcinoma cells (rho-zero 
NT2 cells) with human platelets from HD patients (vs. control individuals) (Figure 5) 
(Ferreira et al., 2010). This model can help to understand if the disease pathology is 
dependent on the mitochondria to a point that HD mitochondria in a cell with a healthy 
nucleus (with no mutations) can cause abnormalities in cell homeostasis. Cybrids have been 
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also used previously to study other neurodegenerative diseases such as Parkinson‟s 
(Trimmer and Bennett, 2009) and Alzheimer‟s diseases (Swerdlow, 2007). 
 
Figure 5 - Creation of HD cytoplasmic hybrids (cybrids). Mitochondria from HD patients (vs. normal individuals- 
controls) are fused with rho-zero cells giving rise to HD cybrids that have normal nuclear genome and mitochondria from 
HD patients. Adapted from Khan et al. (Khan et al., 2007). 
1.3.2. Mouse models 
From KOs of the Htt gene to its genetic alteration, there are a wide variety of mouse models 
presently available to study HD (Bates et al., 1997; Kohan, 2004).  
The KO of the gene hdh was achieved by three groups at the same time (Duyao et al., 1995; 
Nasir et al., 1995; Zeitlin et al., 1995). The nullizygous mice showed an embryonic lethal 
phenotype and some of the heterozygous mice expressing only one copy of hdh (hdh/-) 
were phenotypically normal (Duyao et al., 1995; Zeitlin et al., 1995). In contrast, 
heterozygous mice resulting from a targeting strategy that disrupts exon 5, were reported to 
show neuronal loss in the subthalamic nucleus and the globus pallidus, with some 
behavioral changes (Bates et al., 1997). The explanation for this discrepancy may be in the 
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production of a truncated protein, which could have a dominant effect in the heterozygous 
mice (Bates et al., 1997). Also, chimeric mice were generated by the injection of wild-type 
blastocysts with hdh -/- embryonic stem cells (Reiner et al., 2001). 
Another type of models are the transgenic mice, based in the theory of gain of function of 
mHtt (Kohan, 2004). There are several transgenic mouse models, such as the R6 
(Mangiarini et al., 1996), YAC lines (Hodgson et al., 1999) and Hdh
Q111/Q111
 knock-in mice 
(Wheeler et al., 2000). 
The R6 lines include transgenic mice that express truncated fragments of mHtt gene, and 
present a neurological phenotype similar to HD. There are several of these lines, but the 
R6/1 and the R6/2 have been the most studied. These mice express the exon 1 of the Htt 
gene. The R6/1 has approximately 115 CAG repeats, whereas the R6/2 has 150 CAG 
repeats (Mangiarini et al., 1996). The R6/2 mice exhibit the formation of NIIs (Davies et al., 
1997). They also show other HD-related symptoms, like changes in neurotransmitter 
receptor expression and altered signaling mechanisms (Cha et al., 1998). The R6/1 mouse 
shows similar symptoms, but in a more protracted form (Mangiarini et al., 1996). However 
some of these strains show neuronal cell death. 
The YAC lines include Yeast Artificial Chromossome (YAC) transgenic mice that may 
express the normal (YAC18) or mutant (YAC46, YAC72, YAC128) Htt. The number of 
CAG repeats is defined by the number that follows the acronym YAC, for example the 
YAC128 expresses mHtt with 128 CAG repeats. The mice that express this human mHtt 
show behavioral, electrophysiological, and pathological phenotypes, occurring in very 
similar sequence to that observed in HD patients. This model (YAC128) expresses the full 
length mHtt and shows striatal cell death (Hodgson et al., 1999). 
The Hdh
Q111/Q111
 mice line (HD-repeat knock-in mouse lines) is a homozygous knock-in 
model, where a hybrid gene was generated by the replacement of the mouse Htt exon 1 for 
the human exon 1 of the HD gene carrying an expanded CAG repeat (111 CAG repeats in 
this case) (Wheeler et al., 2000). The Hdh
Q7/Q7
mice, used as a control, are wild-type 
animals that have a regular polyQ expansion (Reis et al., 2011). These mice were used to 
create the ST Hdh
Q111/Q111
 (mutant) and ST Hdh
Q7/Q7
 (wild-type) cell lines, obtained from 
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E14 striatal primordia of Hdh
Q111/Q111 
and Hdh
Q7/Q7
 knock-in mice embryos (Trettel et al., 
2000), and constitute another type of in vitro cell models. 
1.4. MITOCHONDRIAL DYSFUNCTION IN HD PATIENTS 
1.4.1. The mitochondria 
Several studies suggest that abnormal mitochondrial bioenergetics is involved in HD 
progression (Reddy et al., 2009). Mitochondria are responsible for the production of the 
majority of the ATP (adenosine triphosphate) that drives eukaryotic cellular reactions (Enns, 
2003), by oxidative phosphorylation (OXPHOS) (Schatz, 1995). Additionally, 
mitochondria are responsible for the maintenance of calcium homeostasis (Bianchi et al., 
2004; Contreras et al., 2010), Krebs cycle and fatty acid break down (beta-oxidation) 
(Baltzer et al., 2010), apoptotic pathways that involve the release of cytochrome c and 
apoptosis-inducing factor (AIF) (Gogvadze et al., 2006), and the generation of ROS 
(Benard et al., 2007). 
Mitochondria have their own DNA (mtDNA), which comprises 16569-base pairs in a 
circular minichromosome, composed of two complementary strands, and all of the coding 
sequences are contiguous with each other, with no introns (Figure 6) (Anderson et al., 
1981). The expression of mtDNA relies upon mitochondrion-specific protein synthesis, 
carried out though the interplay of nuclear-encoded transcriptional and translational factors, 
with tRNAs and rRNAs synthesized in situ from the corresponding mitochondrial genes. 
The mtDNA contains both protein-encoding genes (analogous to the yeast mit genes), and 
protein synthesis genes (analogous to the yeast syn genes). The 13 mit genes specify seven 
ND subunits (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) of NADH-ubiquinone 
reductase (complex I); three subunits (COI, COII and COIII) of COX (complex IV); 
subunits 6 and 8 of ATP synthase (complex V); and apocytochrome b, which is part of 
ubiquinol-cytochrome c reductase (complex III). The syn genes of mtDNA encode two 
rRNAs (12 and 16S rRNA) and 22 tRNAs that are involved in protein translation of the mit 
gene products. All the subunits of complex II (succinate dehydrogenase-ubiquinone 
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reductase) are encoded by nuclear DNA (nDNA) (Zeviani and Donato, 2004). So, every 
other complex of the mitochondrial respiratory chain (MRC) contains subunits encoded by 
nuclear genes, which are assembled together with the mtDNA-encoded subunits into the 
respective haloenzymes, located in the inner mitochondrial membrane (Scarpulla, 1997). 
The mtDNA is not associated with histones, does not have efficient proofreading during 
replication, or DNA repair system, and to worsen this scenario, the “naked” DNA is often 
exposed to ROS and free radicals, increasing the probability of suffering oxidative damage 
and mutations (Wang et al., 2003). Indeed, mitochondrial oxidative stress indicators are 
elevated in HD human samples (de Souza-Pinto et al., 2008). 
 
Figure 6 – Schematic representation of the human mtDNA. Genomic organization and structural features of human 
mtDNA are depicted in a circular genomic map showing heavy (outside circle) and light (inside circle) strands. myt genes: 
complex I genes, blue; complex III cytb gene, green; complex IV genes, red; complex V genes, yellow. syn genes: tRNA 
genes, grey; rRNA genes, purple. Cyt b, cytochrome b; COI, COII and COIII are cytochrome oxidase (complex IV) 
subunits. Protein coding and rRNA genes are interspersed with 22 tRNA genes (bars denoted by the single-letter amino 
acid code) (Zeviani and Donato, 2004). 
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1.4.2. Mitochondrial dysfunction in HD 
Several studies have shown that the mitochondrion is affected, in a large variety of ways, in 
HD patients. For example, there are alterations in mitochondrial membrane potential, 
calcium buffering capacity, OXPHOS and production of ROS, mitochondrial trafficking 
and dynamics, DNA integrity, and transcriptional regulation of nuclear-encoded 
mitochondrial genes (Reddy et al., 2009; Damiano et al., 2010; Li et al., 2010).  
1.4.2.1. Altered mitochondrial membrane potential in HD 
The mitochondrial membrane potential is affected in HD models. Sawa et al. (1999) 
showed that lymphoblasts derived from lymphocytes from HD patients have increased 
stress-induced apoptotic cell death. In response to apoptotic stress, lymphoblasts from HD 
patients displayed increased mitochondrial membrane depolarization, as compared to 
control lymphocytes, in a CAG repeat expansion-related way (Sawa et al., 1999). Moreover, 
a high sensitivity to calcium-induced permeability transition was also shown in HD mice 
models (Choo et al., 2004). It has also been demonstrated that recombinant mHtt (short N-
terminal fragment) may directly trigger loss of mitochondrial membrane potential and 
permeability transition, likely through an interaction with the outer mitochondrial 
membrane (Choo et al., 2004; Rockabrand et al., 2007). 
1.4.2.2. Altered calcium homeostasis in HD 
The dysregulation of the mitochondrial calcium buffering capacity is closely related with 
the loss of the mitochondrial membrane potential, and it is known that increased cytosolic 
calcium levels are toxic to neurons (Bossy-Wetzel et al., 2004). The impaired calcium 
homeostasis in HD may have different causes, from extra-mitochondrial origins to causes 
related with mitochondrial dysfunction (Damiano et al., 2010). Importantly, previous 
studies showed that the striatal neurons and astrocytes are more vulnerable to the increase 
in calcium compared to their cortical counterparts (Oliveira and Gonçalves, 2009). 
Rockabrand et al. (2007) found out that the first 17 amino acids of the mHtt (that are 
involved in its mitochondrial localization and promote its association with the 
endoplasmatic reticulum and Golgi) are able to disrupt intracellular calcium levels in 
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glutamate-challenged PC12 cells. Incubation of isolated cortical mitochondria with the 
same fragment of mHtt resulted in uncoupling and depolarization of these organelles 
(Rockabrand et al., 2007). Other studies using mitochondria from wild-type and mHtt-
expressing striatal cells showed that mitochondria from mHtt-expressing cells are more 
susceptible when treated with increasing calcium concentrations. Indeed, they were more 
sensitive to calcium-induced decreases in state 3 respiration and mitochondrial membrane 
potential, compared to mitochondria from wild type cells. Also, the presence of mHtt 
decreased mitochondrial calcium-uptake capacity, increasing its cytosolic levels (Milakovic 
et al., 2006). For example, mitochondria in mutant human striatal neurons were shown to 
be unable to handle large calcium loads, being more susceptible to ROS (Lim et al., 2008). 
Gellerich et al. studied brain mitochondria of HD rats expressing Htt with 51 glutamine 
repeats [Htt(51Q)] and concluded that interactions between Htt(51Q) and distinct targets, 
such as aralar and/or the permeability transition pore, may underlie mitochondrial 
dysregulation, leading to energetic depression, cell death, and tissue atrophy in HD 
(Gellerich et al., 2008). Another relevant discovery was that NMDA-induced apoptosis is 
enhanced in medium spiny neurons of transgenic mice expressing 128 glutamines 
(YAC128 (Hodgson et al., 1999)). The authors of this study also showed that NMDA 
receptor-mediated calcium load triggered a strikingly loss of mitochondrial membrane 
potential in these mutant mice and this effect was accompanied by impaired cytosolic 
calcium clearance after removal of NMDA (Hodgson et al., 1999). So, these results suggest 
that the polyQ repeat length influences the mechanism by which mHtt enhances NMDA 
receptor-mediated excitotoxicity (Fernandes et al., 2007). However, Oliveira et al. found 
increased calcium uptake capacity in forebrain mitochondria isolated from 2 transgenic 
mice lines (R6/2 and YAC128) but not in HD knock-in mice expressing 150 polyQ repeats 
(Oliveira et al., 2007). The same authors showed that the neuroprotection induced by 
iHDACs involves more efficient calcium handling, thus improving neuronal survival 
(Oliveira et al., 2006). So, overwhelming evidence clearly suggests that mHtt induces 
increases in intracellular calcium in neurons affected in HD, and this calcium excessively 
enters mitochondria and induces the opening of mitochondrial permeability transition pore, 
leading to decreased mitochondrial ATP levels, neuronal death, and, ultimately, to tissue 
atrophy in HD brain (Figure 7) (Kohan, 2004). 
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Figure 7 – Calcium homeostasis deregulation in HD. Excess mitochondrial Ca2+ may open the mitochondrial 
permeability transition pore in mitochondria from HD patients. In healthy mitochondria, the inner mitochondrial 
membrane provides a highly efficient barrier to ionic flow and protects mitochondria from toxic insults. However, in 
neurons from HD patients, an age-dependent accumulation of mutant Htt oligomers may induce a massive entry of Ca2+ 
into neurons and may promote mitochondrial Ca2+ overload. Excess mitochondrial Ca2+ may promote the opening of the 
mitochondrial permeability transition pore, facilitating sending matrix content out of mitochondria, which may destroy the 
mitochondria, and the neuron, by apoptotic cell death. Adapted from Reddy et al. 2009 (Kohan, 2004). 
 
Also, the cytosolic calcium can be mobilized by the endoplasmatic reticulum (ER) and 
abnormal release of calcium from the ER is likely to exist in neurons expressing mHtt. 
mHtt facilitates the activity of type 1 inositol 1,4,5-trisphosphate receptors (InsP(3)R1) 
(Bezprozvanny, 2010), which is an important aspect since, in the presence of impaired 
mitochondrial calcium handling, and upon the pathologic stimulation of NMDA receptors, 
the increased calcium release from the ER could further increase cytosolic calcium up to 
excitotoxic levels, and thus cause neuronal apoptosis (Damiano et al., 2010). 
1.4.2.3. Altered mitochondrial trafficking and dynamics in HD 
The relevance given to mitochondrial trafficking has increased over time, as it is an 
important mechanism to ensure adequate energy production and calcium handling along 
neuronal processes (Reynolds et al., 2004). mHtt is prone to form aggregates, which can 
physically block mitochondrial movement in neurons (Chang et al., 2006). However, mHtt 
aggregates may also impair mitochondrial movement indirectly, namely by sequestering 
trafficking machinery components and wild-type Htt, which is essential for fast axonal 
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trafficking (Trushina et al., 2004). This defective mitochondrial transport ultimately 
impairs neural transmission, and results in synaptic damage and selective neuronal damage 
or loss (Reddy et al., 2009). Trushina et al. (2004) showed that mitochondria became 
progressively immobilized and stopped more frequently in neurons from HD animal 
models. Indeed, these defects occurred early in the development of disease, before the onset 
of measurable mitochondrial abnormalities (Trushina et al., 2004). Also, wild-type Htt, 
trafficking motors, and mitochondrial components were selectively sequestered by mHtt in 
postmortem brain specimens from HD patients (Trushina et al., 2004). Chang et al. (2006) 
suggested that, in cortical neurons, an early event in HD pathophysiology may be the 
aberrant mobility and trafficking of mitochondria caused by cytosolic Htt aggregates 
(Chang et al., 2006). Moreover, Orr et al. (2008) observed that, before aggregate formation, 
N-terminal mHtt fragments could directly impair mitochondrial function (Orr et al., 2008). 
Abnormalities in the mitochondrial dynamics have also been associated with HD (Reddy et 
al., 2009). Mitochondrial shape and structure are maintained by two opposing forces: 
mitochondrial fusion and fission (Chan, 2006; Reddy, 2007). Fission is controlled and 
regulated by the dynamin-related protein (Drp1) and mitochondrial fission 1 (Fis1), the 
latter being localized to the outer-membrane of mitochondria. Both proteins are large 
GTPases belonging to the family of dynamin. In HD neurons, mitochondrially generated 
free radicals activate Fis1 and promote an increase in mitochondrial fragmentation, which 
in turn produces defective mitochondria that ultimately damage neurons (Reddy et al., 
2009). Also, cells expressing red fluorescent protein (RFP)-tagged Htt containing 74 polyQ 
repeats presented mitochondria displaying reduced movement and reduced fusion, 
compared to cells expressing RFP-Htt protein with only 28 polyQ repeats (Wang et al., 
2009). 
1.4.2.4. Loss of mitochondrial DNA integrity in HD 
The absence of a large variety of mechanisms to protect the mtDNA (as referred above) is 
responsible for age-dependent cellular damage, a fact that is thought to play an important 
role in HD. Acevedo-Torres et al. (2009) showed that, in mice models of HD, mtDNA 
damage is an early biomarker for HD-associated neurodegeneration, and suggested that this 
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damage may contribute for the disease pathogenesis. Indeed, they found out that young HD 
mice were able to repair mtDNA damage, whereas aged mice showed persistent lesions to 
the mitochondrial genome. This persistent damage to mtDNA may result from increased 
ROS production and/or from loss of repair capacity. (Acevedo-Torres et al., 2009). Other 
investigators showed that mHtt and instability in polyQ repeats may cause mtDNA damage 
in neurons from HD patients and increase the rate of mtDNA deletions compared to the 
controls (Banoei et al., 2007). Polidori et al. (1999) further showed that there is an increase 
in 8-hydroxy-2-deoxyguanosine (OH
8
dG, a marker of oxidative DNA damage) in the 
mtDNA of cerebral cortex and cerebellum of HD patients. These increased levels of 
OH
8
dG are responsible for nucleotide base misparing, resulting in DNA point mutations 
(Polidori et al., 1999). Other studies detected higher levels of OH
8
dG in parietal cortex of 
HD patients, but not in frontal cortex or cerebellum, suggesting that region-specific damage 
to mtDNA may play a causative role in mitochondrial dysfunction observed in HD. Also, 
the hypothesis that mtDNA may be particularly vulnerable in HD is supported by the high 
levels of the mtDNA
4977
 deletion found in temporal and frontal lobes of HD patients, 
compared with age-matched control subjects (Yang et al., 2008). Thus, age-dependent 
mtDNA damage may have an important role in late-onset HD and, on the other hand, HD 
mitochondrial pathology (such as higher levels of ROS, respiratory impairment) may 
enhance mtDNA mutations, increasing the mitochondrial pathology. 
1.4.2.5. Altered transcription in HD – the link to mitochondrial 
biogenesis and susceptibility 
As mentioned before, mHtt can bind several transcription factors, including TATA binding 
proteins, Sp1, and the nuclear scaffold protein NAKAP (Reddy et al., 2009). mHtt 
interaction with transcription factors may interfere with gene expression, activity, and 
transcriptional regulation in HD neurons. For example, PGC-1α (peroxisome proliferation-
activated-γ (PPARγ) coactivator 1α), a potent suppressor of ROS, and the mitochondrial 
transcription factor A (TFAM), a regulator of mtDNA expression and  a modulator of 
mitochondrial base excision repair, were found to be decreased in HD post mortem brains, 
in cell lines expressing mHtt and in HD mouse models (Cui et al., 2006; Canugovi et al., 
2010; Kim et al., 2010). PGC-1α is a transcription coactivator that interacts with a range of 
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transcription factors involved in a wide variety of biological responses, including adaptive 
thermogenesis, energy metabolism and mitochondrial biogenesis in several tissues, 
including the brain (Liang and Ward, 2006; Kim et al., 2010). Also, some authors suggest 
that its activation protects HD neurons from mitochondrial toxicity caused by mHtt, 
because the basal levels of some ROS defense enzymes (SOD1- copper/zinc superoxide 
dismutase; SOD2 – Manganese SOD; catalase) are diminished in the heart and brain of 
PGC1α-deficient mice (St-Pierre et al., 2006). Importantly, Cui et al. (2006) found a 
decrease in mRNA expression of PGC-1α in several models of HD, suggesting that mHtt 
interferes with the formation of the CREB/TAF4 complex that regulates transcription of the 
gene encoding PGC-1α (Cui et al., 2006). Also, mHtt increases p53 levels (associated with 
tumor suppression), which in turn, results in increased Bax and Puma expression, 
mitochondrial damage and neuronal loss (Bossy-Wetzel et al., 2008). Figure 8 shows 
mitochondrial-related transcriptional abnormalities that happen due to the presence of mHtt.  
iHDACs (SB and TSA) were found to improve mitochondrial-dependent calcium handling 
and mitochondrial membrane potential in striatal cell models of HD expressing the full-
length Htt. Also, treatment with these inhibitors was correlated with increased 
mitochondrial activity (Oliveira et al., 2006). Oliveira et al. (2006) showed that iHDACs 
increase histone H3 acetylation, suggesting that beyond the simple restoration of “normal” 
gene expression levels, iHDACs may also enhance the expression of genes (and proteins) 
that exert therapeutically effects on neuronal function (Oliveira et al., 2006). 
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Figure 8 – Mutant Htt impairs mitochondrial function by transcriptional dysregulation of nuclear-encoded 
mitochondrial proteins and by direct effects on the organelle. (a) mHtt blocks the PGC-1α promoter via inhibition of 
the CREB transcriptional activator, resulting in decreased PGC-1α expression. (b) Lower PGC-1α levels will decrease 
PPARγ-mediated expression of nuclear-encoded mitochondrial proteins that are necessary for respiration and oxidative-
damage defense. (c) mHtt can have direct effects on mitochondria, blocking the respiratory complex II, as does 3-
nitropropionc acid (3-NP). Respiratory inhibition, in turn, leads to decreased energy production and mitochondrial 
transmembrane potential, in addition to increased reactive oxygen species (ROS) generation. The bioenergetic decline 
caused by transcriptional deregulation and by the direct effect of mHtt on mitochondria can cause increased vulnerability 
to excitotoxic stimuli and amplification of the mitochondrial damage by calcium-mediated mitochondrial-permeability-
transition-pore (mPTP) opening. Abbreviations: CBP, CREB binding protein; cI–cV, respiratory complexes I–V; Cyt c, 
cytochrome c; Gpx1, glutathione peroxidase 1; IM, inner membrane; mtDNA, mitochondrial DNA; mtTFA, 
mitochondrial transcription factor A; OM, outer membrane; UCP1, uncoupling protein 1; SOD1-2, superoxide dismutase 
[Cu-Zn] and superoxide dismutase [Mn]; NRF, nuclear respiratory factor; CREB, cAMP response element-binding; Sp1, 
specificity protein 1; TAF4, transcription initiation factor TFIID subunit 4; PGC1α, peroxisome proliferator-activated 
receptor-γ coactivator 1-α; PPAR-γ, peroxisome proliferator-activated receptor γ (Bossy-Wetzel et al., 2008). 
1.4.2.6. Altered respiratory chain and pyruvate dehydrogenase in HD – 
consequences for altered energy metabolism 
Neuronal homeostasis is highly dependent on the mitochondrial respiratory chain in a way 
that its impairment potentially leads to neurodegeneration. Functional respiratory 
complexes are required to generate the proton motive force, generating and maintaining 
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mitochondrial membrane potential, which fuels ATP generation, calcium-handling, and 
ROS generation/detoxification. Importantly, respiratory chain impairment is known to be 
involved in HD (Oliveira, 2010). 
Analysis of post mortem striatal samples has shown that HD patients have a severe 
reduction in the activity of complex II/III and mild reduction of complex IV activity 
(Damiano et al., 2010; Oliveira, 2010). No changes were observed in pre-symptomatic or 
early symptomatic (grade 1) patients (Guidetti et al., 2001) or in their blood cells, but a 
massive loss of aconitase activity was found in the caudate (~90%) and putamen (~70%) 
(Tabrizi et al., 1999; Sorolla et al., 2008). Loss of pyruvate dehydrogenase (PDH) activity 
was also shown (Sorbi et al., 1983). Interestingly, in vivo striatal glycolytic metabolism 
(predominantly astrocytic) was found to be selectively impaired in HD patients, suggesting 
astrocyte dysfunction (Powers et al., 2007). In mice genetic HD models expressing full-
length mHtt, there is no impairment of the mitochondrial respiratory complexes I-IV 
(Guidetti et al., 2001), with the exception of the mouse model of HD R6/2 (Zourlidou et al., 
2007). Again, in the R6/2 mice, aconitase and PDH have been found to be decreased 
(Zourlidou et al., 2007). Results obtained using cell lines as HD models showed  a 
significant decrease in mitochondrial respiratory rates, but no impairment in the activity 
individual respiratory complexes (Milakovic and Johnson, 2005). Also, this difference in 
the respiratory rates disappears when isolated mitochondria are assessed (Milakovic et al., 
2006), suggesting that detection of some mitochondrial deficits requires a preserved cellular 
context. The enzyme succinate dehydrogenase (from complex II) is present in reduced 
levels in some HD models. However, it is still a matter of some controversy, since many 
models fail to show a reduction in the levels of this enzyme (Damiano et al., 2010). 
As described above, ATP production via OXPHOS is very important to the cellular 
integrity, and impairment of this pathway contributes to HD pathogenesis (Oliveira, 2010). 
Concordantly, Milakovic & Johnson (2005) have found decreased mitochondrial respiration 
and ATP levels in the STHdh
Q111/Q111 
HD cellular model (Milakovic and Johnson, 2005). 
Conversely, an increase in ATP levels was observed in N171-82Q mice brain (which 
expresses truncated mHtt) (Oláh et al., 2008). Glycolysis stimulation, as a compensatory 
mechanism, has been thought to justify this result (Oliveira, 2010). HD patients also 
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present high levels of lactate in both the striatum and cortex (Jenkins et al., 1993; 
Koroshetz et al., 1997), and increased lactate/pyruvate ratio in the cerebrospinal fluid (CSF) 
(Koroshetz et al., 1997). Recently, Ferreira et al. (in our lab) studied cybrids obtained from 
the fusion of HD platelets with NT2 rho-zero cells, depleted from mtDNA, and showed that 
these HD cybrid lines possessed inherent bioenergetically dysfunctional mitochondria 
derived from HD patients‟ platelets. Mitochondrial dysfunction was found at the level of 
PDH, upstream the OXPHOS, affecting amino acid metabolic fluxes and the cellular 
bioenergetics, through glycolysis stimulation. This seemed to assume a greater importance 
in promoting ATP production, which was higher in HD cybrids compared to controls. 
Indeed, PDH expression was decreased in HD cybrids, and a trend was found for an 
increase in phosphorylation in specific residues of the subunit E1alpha (Ser 232, Ser 293 
and Ser 300), which lead to lower PDH activity (Ferreira et al., 2011). The 
mammalian PDH complex (PDC) consists of six different subunits (Reed et al., 1985; Pons 
et al., 1988): three catalytic enzymes, two regulatory enzymes and a protein X (E3BP). The 
three catalytic enzymes are PDH (E1), which is composed of E1alpha and E1beta subunits; 
dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3). The E1 and E2 
subunits are unique to PDC, while the E3 subunit is common to two other mitochondrial α-
keto acid dehydrogenase complexes (Reed et al., 1985; Pons et al., 1988; Patel and Roche, 
1990) The two regulatory enzymes are PDH-specific kinase (PDK) and PDH-specific 
phosphatase (PDP). These regulatory enzymes control the overall activity of the PDC by a 
reversible cycle of phosphorylation (inactivation) and dephosphorylation (reactivation) of 
the E1alpha subunit (Reed et al., 1985; Patel and Roche, 1990). Also, E1alpha subunit is 
encoded by nuclear DNA [X-linked pyruvate dehydrogenase (E1) α subunit gene (PDHA1), 
(Lissens et al., 2000)].  
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1.5. OBJECTIVE 
Since the discovery of the Htt gene, HD has become the center of several studies around the 
world. Among all the cellular dysfunctions observed in HD, mitochondrial dysfunction is 
one of the most studied. Our group recently described that PDH, a nuclear-encoded 
mitochondrial enzyme, is deregulated in HD cybrids, along with other bioenergetic changes 
(Ferreira et al., 2011).  
Currently, there is no effective treatment to HD. However, previous evidence suggests that 
insulin and IGF-1 may offer potential therapeutic protection against HD. Thus, we 
hypothesized that both compounds could prevent or attenuate the HD bioenergetic deficits, 
specially those related to PDH abnormalities. Furthermore, iHDACs can also be used to 
revert HD dysfunction, ameliorating transcriptional alterations caused by mHtt. Moreover, 
to help studying the importance of in mitochondrial dysfunction in HD, future research 
could benefit from new cybrid lines made from rho-zero cells obtained from human 
lymphoblasts. So, our main objective was to study mitochondrial dysfunction in HD and 
potential therapeutic strategies directed to this defect. For this purpose, in this work we 
aimed to: 
1. Confirm the importance of PDH dysfunction and validate this protein as a potential 
therapeutic target in HD; 
2. Assess the role of PDH in insulin and IGF-1 neuroprotection in a model of known 
bioenergetic dysfunction; 
3. Determine the ability of iHDACs to protect from bioenergetic dysfunction 
involving PDH deficiency; 
4. Create new rho-zero cells from human lymphoblasts. 
  
 
 
 
CHAPTER 2 – MATERIAL AND 
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2.1 MATERIAL 
Lymphoblastoid cell lines were obtained from NIGMS Human Genetic Cell Repository 
(CORIELL Institute for Medical Research, New Jersey, and USA). Fetal Bovine Serum 
(FBS), B27 supplement and penicillin/streptomycin were from Gibco (Paisley, Scotland, 
UK). Insulin from porcine pancreas, trypsin type IX-S from porcine pancreas, IGF-1, 
Glucose-6-phosphate (G6P), Deoxy-D-Glucose (DG), albumin from bovine serum (BSA), 
trypan blue (0.4%), nicotinamide adenine dinucleotide phosphate hydrate (NADP), 
nicotinamide adenine dinucleotide hydrate (NAD), ADP, G6P dehydrogenase (G6P-DH), 
hexokinase, creatine kinase, CoASH, thiamine pyrophosphate (TPP), ethidium bromide 
(EtBr), pyruvate, uridine, acetyl-L-carnitine (ALCAR),  dichloroacetate (DCA), trichostatin 
A (TSA), sodium butyrate (SB) and 4-phenylbutyrate (PB) were from Sigma Aldrich (St. 
Louis, MO, USA). Calcium Chloride, MgCl2, high-performance liquid chromatography 
(HPLC) columns were from Merck (Darmstadt, Germany). Bio-Rad Protein Assay was 
from Bio-Rad (Hemel Hempstead, UK). Lactate and phospho-PDH in-cell ELISA kit were 
from Abcam (Cambridge, UK). DMEM medium was from Sigma. All other reagents were 
of analytical grade. 
2.2. METHODS 
2.2.1.Lymphoblastoid cell lines culture  
Lymphoblast cell lines were obtained from CORIELL Institute. In this study, lymphoblast 
cell lines derived from HD affected patients containing heterozygous expansion mutation 
(n=2) or from unaffected aged-matched voluntary subjects (control siblings) (n=3), used in 
this work as CTR lymphoblasts (Table 1).  
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Table 1 - Demographic and genetic characteristics of HD and control 
lymphoblast cell lines. 
Cell 
line 
Gender 
Age of 
onset 
Age at 
Sampling 
Expanded 
CAG 
Affected/unaffected Race 
#5678 male 48 yrs 58 yrs 42/18 affected Caucasian 
#5610 female 40 yrs 52 yrs 47/18 affected Caucasian 
#5724 male - 51 yrs - unaffected Caucasian 
#4800 female - 45 yrs - unaffected Caucasian 
#4808 male - 42 yrs - unaffected Caucasian 
Catalogue number of Caucasian lymphoblasts and detailed information about gender, age of disease 
onset, age of sampling and respective CAG repeats. 
Upon reception, cell culture flasks were incubated unopened overnight at 37°C. In the 
following day, cells were counted and splited to yield a cell density of 0.2-0.5 x 10
6
 viable 
cells/ml in RPMI 1640 medium supplemented with 15% of non-inactivated FBS, 2 mM 
glutamine and 50 µg/ml streptomycin plus 100 IU/ml penicillin in an incubator chamber 
containing 95% air, 100% humidity, 5% CO2, in upright position, with loose caps. In these 
conditions, lymphoblastoid cell lines grew in suspension, with cells clumped in loose 
aggregates. When desired, these aggregates were dissociated by gently agitating the culture 
or by gentle trituration with a pipette. Every three to four days, the medium was changed 
upon cell centrifugation or by gentle aspiration, and refilled with fresh medium. 
2.2.2.Rho-zero production  
In order to produce rho-zero cells, lymphoblasts were plated at a density of about 0.3x10
6
 
cells/ml, and subcultured in culture medium containing 100 µg/ml sodium pyruvate and 
100 µg/ml uridine, in the absence or in the presence of 50, 75 or 100 ng/ml EtBr. By using 
this approach two independent experiments were performed, as described in Figure 9. 
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Figure 9 – Schematic representation of the two independent experiments performed in order to produce Rho-zero 
cells. A) CTR (CTR 5724) and HD (HD 5678) lines were exposed to 0, 50, 75 or 100 ng/ml of Ethidium Bromide (EtBr). 
Thirty five days after the beginning of the experiment the proliferation levels of all cell lines were evaluated. At that time 
point, an aliquot of each cell line was maintained in the absence of EtBr (blue arrow) for 25 days, and the oxygen 
consumption rate was measured in all cell lines. Fourty six days after the beginning of the experiment, samples of all cell 
lines were used to quantify the number of mitochondrial DNA copies. EtBr exposure was stopped by 64 days (green 
arrow), and successive measures of the oxygen consumption rate were then performed. An aliquot of cell suspension was 
let growing in the presence of EtBr for 1 more month (red arrow). However, in these conditions the cells died due to an 
extremely slow proliferation rate. Unfortunately, the HD line was found to be contaminated near the end of the 64 days of 
EtBr exposure. B) In the second experiment two CTR lines (CTR 4800 and CTR 4808) and two HD lines (HD 5678 and 
HD 5622) were exposed to 0, 50 and 75 ng/ml of EtBr. Fifty six days after the beginning of the experiment the EtBr was 
removed from the medium and the oxygen consumption rate was evaluated 8 and 17 days after this time point. Thirty one 
days after the EtBr removal, a cell sample was used in order to evaluate the number of mitochondrial DNA copies. The 
cell line HD 5610 was discontinued, due to an extremely slow proliferation rate, invalidating its use for the creation of 
rho-zero lines. 
2.2.3.Striatal cell lines 
Immortalized striatal neurons derived from knock-in mice expressing full-length normal 
(STHdh
7/7
, clone 2aA5, referred as wild-type cells) or full-length mHtt with 111 glutamines 
(STHdh
111/111
, clone 109-1A, referred as mutant cells) were generously provided by Dr. 
Marcy MacDonald (Massachusetts General Hospital, Charleston, MA) and treated 
according to slight modifications of established procedures (Trettel et al., 2000). Briefly, 
cells were grown adherent at 33ºC in DMEM medium supplemented with 10% fetal bovine 
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serum (FBS), 4 mM glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 400 g/ml 
geneticin, in an atmosphere of 95% air/5% CO2. STHdh cells were plated on 100 mm-
diameter dishes at a density of 1x10
6
 cells/dish to obtain cellular extracts. For enzyme 
activity assays, cells were plated on 96-well plates at a density of 2.5x10
4
 cells/well, on 24-
well plates at 5x10
4
 cells/well or on 6-well plates at a density of 0.5x10
6
 cells/well. For the 
viability tests, cells were plated on 12-well plates at a density of 3x10
4
 cells/well. Twenty 
four hours before the experiment (and one day after cell plating), the cells were incubated 
with TSA (10 nM, 50 nM and 100 nM), SB (100 μM, 250 μM and 500 μM), PB (100 μM, 
250 μM and 500 μM), ALCAR (100 μM, 500 μM and 5 mM), DCA (300 μM, 1 mM and 3 
mM), insulin (0,1 nM) and  IGF-1 (1 nM). 
2.2.4.Total extracts 
Adherent cells were washed two times in ice-cold phosphate-buffered saline (PBS) 
containing (in mM): 137 NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4.2H2O, pH 7.4, and then 
scraped in 500 μl lysis buffer (150 mM NaCl, 50 nM Tris, 5 mM EGTA, 1% Triton X-100; 
0.5% deoxycholate, 0.1% SDS, pH 7.5) supplemented with 1 mM DTT, 1 mM PMSF and a 
1 μg/mL protease cocktail inhibitor (containing chymostatin, pepstatin A, leupeptin and 
antipain). Cellular extracts were frozen 3 times in liquid nitrogen, then sonicated for 30 s 
and centrifuged at 20800 g for 10 min (Eppendorf Centrifuge 5417R) to remove cellular 
debris. The pellet was discarded, the supernatant (total extract) was collected and protein 
content quantified by Bio-Rad method (BioRad, Hercules, CA, and USA). Extracts were 
stored at -20ºC until used for western blotting experiments. 
For the analysis of enzymatic activities, cell extracts were obtained by scraping the cells 
using 100 μl of a buffer containing 25.0 mM KH2PO4, 0.5 mM EDTA, pH 7.25, 
supplemented with 0.01% Triton X-100. For lactate dehydrogenase activity (LDH) assay, 
cells were scraped with 20 μl of 10 mM HEPES, pH 7.4 with 0.5% of Triton X-100. 
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2.2.5.PDH and Lactate dehydrogenase activity 
Enzyme activities were determined by following the rate of NADH formation or 
consumption at 340 nm, using a microplate reader Spectra Max Plus 384 (Molecular 
Devices, USA). For PDH activity, 9 µg of cell sample were mixed with 2.5 µM rotenone, 
0.5 mM of NAD
+
, 0.2 mM thiamine pyrophosphate (TPP
+
), 0.04 mM Coenzyme A and 4 
mM pyruvate. For LDH activity, 0.19 μl of reduced NADH were added to 6.45 μl of the 
sample mixed with 1.57 mM of sodium pyruvate, prepared in Tris/NaCl pH 7.2 (81.3 mM 
of Tris and 203.3 mM of NaCl). Monitoring of the NADH consumption or formation was 
performed at 30ºC. 
2.2.6.Determination of PDH E1alpha subunit protein levels 
and phosphorylation 
PDH expression and phosphorylation were assessed using a kit from MitoSciences (Oregon, 
USA), following the manufacturer instructions and using the solutions provided in the kit. 
Briefly, cells were plated at a 96-well plate and fixed with 3.7% formaldehyde in PBS. 
Cells were permeabilized, blocked and incubated overnight with total PDH E1alpha 
combined with another antibody against the phosphorylated forms of PDH E1alpha at pSer 
232, pSer293 or pSer 300. Separate secondary antibodies were used against PDH E1alpha 
or the phosphorylated serines, and developed by dual colorimetric detection. Cell density 
was normalized after Janus Green staining. Absorbance was monitored using a microplate 
reader Spectra Max Plus 384 (Molecular Devices, USA). 
2.2.7.Cell viability tests 
At the time of cell incubation with the different compounds, the culture medium was 
replaced for fresh medium. The nuclear morphology of the striatal wild-type and mutant 
cells exposed to different concentrations of different compounds (TSA, PB, SB, ALCAR 
and DCA) was analyzed by fluorescence microscopy, by using a double staining procedure 
with Hoechst 33342 and propidium iodide (PI). Following a washing step with microscopy 
medium (120 mM NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 20 mM HEPES, 5 mM NaHCO3, 
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1.2 mM Na2SO4 and 15 mM glucose) the cells were incubated with 4 µg/ml Hoechst 33342 
for 15 min, washed two times with microscopy medium, and incubated with 4 µg/ml PI for 
3 min, in the dark, at room temperature. Cells were washed 3 times in microscopy medium, 
in order to remove extracellular dyes, and further examined and scored using the 
AxioObserver Z1 upright microscope (Zeiss, Jena, Germany). 
2.2.8.Analysis of hydroperoxides  
Cells (plated in 96-well plates) were loaded for 30 min with 20 µM DCFH2-DA, a stable 
non-fluorescent cell permeable compound, at 37°C in Na+ medium (135 mM NaCl, 5 mM 
KCl, 0.4 mM KH2PO4, 1.8 mM CaCl2, 20 mM HEPES, 5.5 mM glucose, pH 7.4). When 
internalized by the cell, DCFH2-DA is hydrolyzed to DCFH by intracellular esterases, 
retained inside the cell, and rapidly oxidized to the highly green fluorescent component 2,7-
dichlorofluorescein (DCF) by endogenous hydroperoxides. Intracellular levels of peroxides 
were measured by continuously following DCF fluorescence (480 nm excitation, 550 nm 
emission) for 1 h at 37°C, using a microplate reader Spectrofluorometer Gemini EM 
(Molecular Devices, USA). In order to correct the DCF fluorescence values for variations 
in total protein content in the wells, cell protein in each well was quantified by the BioRad 
protein assay.  
2.2.9.Assessment of lactate and pyruvate  
Cells were washed with ice-cold PBS and extracted with 0.6 M perchloric acid 
supplemented with 25 mM EDTA-Na
+
. Cell extracts were centrifuged at 20,800 g for 5 min 
at 4°C in order to remove cell debris. Lactate and pyruvate were determined in the 
supernatant by using kits from Abcam (Cambridge, UK), according to manufacturer‟s 
instructions. 
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2.2.10. Assessment of ATP, ADP and phosphocreatine levels 
Cells were washed with ice-cold PBS, scraped, extracted with 0.6 M perchloric acid, 
supplemented with 25 mM EDTA-Na
+
, and centrifuged at 20,800 g for 5 min at 4°C. The 
resulting pellet was solubilized with 1 M NaOH and further analyzed for total protein 
content by the Bio-Rad Protein assay. After neutralization with 3 M KOH/1.5 M Tris, 
samples were centrifuged at 20,800 g for 5 min at 4°C. The resulting supernatants were 
assayed for ATP, ADP and AMP determination by separation in a reverse-phase HPLC, 
with detection at 254 nm, as described previously (Stocchi et al., 1985). The 
chromatographic apparatus used was a Beckman-System Gold controlled by a computer, 
and the column used was a Lichrospher 100 RP-18 (5 µm). An isocratic elution with 100 
mM phosphate buffer (KH2PO4), pH 6.5 and 1% methanol was performed with a flow rate 
of 1 ml/min. Peak identity was determined by following the retention time of standards.  
To assess the phosphocreatine (PCr) levels in the same samples used for the determination 
of ATP and ADP, a reaction solution (in mM: 50 triethanolamine, 12.7 NADH, 100 MgCl2, 
500 glucose, 21.2 ADP) supplemented with 87.5 kU/l G6P-DH and 70 kU/l hexokinase, 
was added to the samples. Determination of intracellular PCr levels was performed by 
following NADP
+
 reduction at 340 nm, mediated by ATP production by creatine kinase, by 
using a Microplate Spectrophotometer SpectraMax Plus 384 (Molecular Devices, USA), 
according to a previously described method (Heinz and Weißer, 1985) 
2.2.11. Western blotting 
Total extracts, obtained as described previously, were denatured with denaturing buffer (50 
mM Tris-HCl pH 6.8, 2% SDS, 5% glycerol, 600 mM DTT, 0.01% bromophenol blue) at 
95 ºC, for 5 min. Equivalent amounts of protein were separated on a 10-12% SDS-PAGE 
gel electrophoresis (Laemmli, 1970) and electroblotted onto polyvinylidene difuoride 
(PVDF) membranes (Milipore, Billerica, MA, USA). The membranes were blocked for 1 h 
in Tris-buffered saline (TBS) solution containing 0.1% Tween (TBS-Tween) and 5% fat-
free milk or 5% of bovine serum albumin (BSA), followed by an overnight incubation with 
primary antibodies (Table 2), at 4ºC, with gentle agitation. Membranes were then washed 3 
Material and Methods 
41 
 
times, for 15 min, with TBS-Tween, and incubated with secondary antibodies (1:20000) for 
1 h, at room temperature with gentle agitation. Immunoreactive bands were visualized due 
to alkaline phosphatase activity that catalyses the conversion of ECF substrate to a highly 
fluorescent product reagent. This product strongly fluoresces at 540–560 nm when the blots 
are illuminated with UV light (maximum excitation at 430 nm), by using a BioRad Versa 
Doc 3000 Imaging System. 
Table 2- List of the primary antibodies used in this work. 
Primary Antibody Molecular Weight Reference Dilution 
Secondary 
antibody 
Anti-acetyl-Histone 3 17 kDa 
06-599 
(Millipore) 
1:20000 rabbit 
Anti-Histone 3 17 kDa 
#9715 (Cell 
Signaling) 
1:2000 rabbit 
Anti-PDH kinase 1 
(PDK) 
47 kDa 
#3820 (Cell 
Signaling) 
1:1000 rabbit 
Anti-PDH phosphatase 
(PDPc) 
53 kDa 
Sc-87354 
(Santa Cruz) 
1:200 goat 
Anti-Tubulin 50 kDa T6199 (Sigma) 1:1000 mouse 
2.2.12. Proliferation assays 
The trypan blue test is commonly used to evaluate cell viability in a cell suspension. It is 
based on the principle that live cells having intact plasma membranes exclude the dye, 
whereas dead cells do not. In order to study the rate of division of the lymphoblast cell lines, 
cells were seeded, in duplicates, at a density of 0.3x10
6
 cell/ml, in 96-well plates, and 
cultured for 5 days. Every other day, an aliquot of cell suspension was diluted two times in 
0.1 % trypan blue and counted by using a hemocytometer, under an inverted light 
microscope. 
2.2.13. Oxygen consumption  
In order to measure the rate of oxygen consumption by the cells, one day before the 
experiment the cells were counted and seeded with fresh culture medium at a density of 
0.6x10
6
 cells/ml. 5x10
6
 cells were centrifuged at 77 x g for 5 min, washed 1x in pre-
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warmed (37 ºC) Krebs buffer (containing (in mM): 132 NaCl, 4 KCl, 1 CaCl2, 1.2 
NaH2PO4, 1.4 mM MgCl2, 6 Glucose, 10 HEPES, pH 7.4), followed by a quick (on-off) 
spin at 2600 x g. The cells were ressuspended in 300 µl Krebs buffer, and the rate of O2 
consumption was recorded under constant magnetic stiring, by using an oxygen electrode 
chamber (DW1, Clark electrode, Hansatech, UK), previously calibrated for the oxygen 
dissolved at 37ºC in Krebs buffer (maximum) and in N2-saturated water (minimum). After 
recording the basal rate of oxygen consumption, potassium cyanide (KCN) (700 μM) was 
added at the end of the experiment, in order to check if O2 was consumed by mitochondrial 
complex IV. Results were expressed in nmol O2/ml/min/5 x 10
6
 cells. 
2.2.14. Statistical analysis 
Results are expressed as mean ± SEM of the indicated number of independent experiments. 
Comparisons between multiple groups were performed with two-way or one-way analysis 
of variance (ANOVA), followed by Bonferroni post-hoc test, for comparison between 
experimental groups. Comparison between two groups was performed by the Student´s t 
test (GraphPad Prism Version 5.0).  Significance was accepted at p<0.05. 
  
 
CHAPTER 3 – 
PDH DYSFUNCTION IN HD
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As previously mentioned, PDH is known to be altered in HD human brains (Sorbi et al., 
1983). Our lab recently showed that HD cybrids also showed decreased PDH activity and 
protein levels, and increased phosphorylation/inactivation (Ferreira et al., 2011), which 
suggested mitochondrial bioenergetic impairment in HD. In line with these findings, we 
aimed at confirming the occurrence of PDH alterations in the striatal cell line 
STHdh
Q111/Q111
 (mutant), compared to STHdh 
Q7/Q7
 (wild-type) cells, to assess the role of 
PDH in some of the cellular abnormalities observed in the disease. 
3.1. RESULTS 
3.1.1.PDH function is altered in STHdh
Q111/Q111
 cells 
PDH activity can be regulated by phosphorylation (Kolobova et al., 2001), expression and 
even by hormones (Behal et al., 1993), depending on the tissue. The levels of the E1alpha 
subunit of PDH, along with its phosphorylation levels at three regulatory serines (Ser 232, 
Ser 293 and Ser 300) were assessed using a kit based in an immunocytochemistry protocol 
(Figure 10A,B). We observed that the total levels of the PDH E1alpha subunit (Figure 10A) 
were decreased by almost 50% in mutant cells, when compared with wild-type cells. Figure 
10B shows that, in mutant cells, all the three regulatory serines exhibited higher 
phosphorylation levels. This increase in phosphorylation was more pronounced in the Ser 
232 (about 2 times the value observed in the wild-type cells). PDH activity was also 
assessed by following the production of NADH that accompanies pyruvate conversion into 
Acetyl-CoA. In Figure 10C, a pronounced decrease in the PDH activity in mutant cells was 
evident, when compared to wild-type cells. 
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Figure 10- PDH activity, subunit expression and phosphorylation is altered in mutant cells (STHdhQ111/Q111). The 
protein expression levels and the phosphorylation of the PDH subunit E1alpha were assessed using a kit, as described in 
Materials and Methods. PDH activity was measured in total extracts of wild-type and mutant cells. Total PDH E1alpha 
expression (A) and phosphorylation at serines 232, 293 or 300 (B) were analyzed in wild-type and mutant cells. Mutant 
cells showed decreased levels of PDH E1alpha subunit, while phosphorylation of the three serines was increased. A 
decrease in PDH activity was also observed in mutant cells (C). Statistical analysis was performed by Student's t-test; ttt 
p<0.001 compared with respective wild-type control; Data are the mean ± S.E.M of total PDH E1alpha /Janus Green, 
phosphorylated form/ total PDH E1alpha or PDH activity (slope)/protein content. For each graph, the average value 
obtained for wild-type was considered 100%. Absolute values were 3.60 ± 0.98 (A), 4.32 ± 1.42 for pSer 232 (B), 3.94 ± 
1.16 for pSer 293 (B), 3.28 ± 0.62 for pSer 300 (B) and 1178.00 ± 247.00 AU/min/mg protein (C). 
3.1.2.Decreased cell viability and increased ROS production in 
STHdh
Q111/Q111
 cells 
HD is characterized by a large number of cellular abnormalities, including an increase in 
ROS production that may lead to protein oxidation and, ultimately, to a decrease in cell 
viability (Sorolla et al., 2010).  
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In this work, we used fluorescence microscopy to assess the basal viability of wild type and 
mutant cells. Mutant cells presented lower cell viability (~70%), when compared with wild-
type cells (~90%). Accordingly, the number of apoptotic mutant cells was over twice than 
those observed in the wild type cell line (Figure 11A). The mutant cell line also presented a 
high level of necrotic cells.  
To assess the role of PDH dysfunction in cell viability, cells were exposed to 
dichloroacetate (DCA) or acetyl-L-carnitine (ALCAR) for 24h before the experiments. 
DCA is a PDK inhibitor that leads to increased PDH activity and decreased E1alpha 
subunit turnover (Fouque et al., 2003), whereas ALCAR allows overpassing the PDH 
impairment, by „feeding‟ acetyl-CoA directly into the Krebs cycle (Jones et al., 2010). We 
observed that, in wild-type cells, ALCAR (0.5-5 mM) and DCA (0.3-3 mM) did not 
significantly affect cell viability (Figure 11B). However, at 100 μM, ALCAR had a 
negative effect in cell viability. In mutant cells (Figure 11C), ALCAR (0.1-0.5 mM) and 
DCA (0.3- 1 mM) did not affect cell viability, necrosis or apoptosis. Interestingly, the 
higher concentrations of both compounds (5 mM ALCAR and 3 mM DCA) had a positive 
effect in cell viability, increasing the percentage of viable cells and decreasing the 
percentage of apoptotic cells.  
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Figure 11- STHdhQ111/Q111 cells show decreased viability. After 24h incubation with different concentrations of acetyl-
L-carnitine (ALCAR) and dichloroacetate (DCA), wild type (B) and mutant (C) cells were stained with fluorescent 
Hoechst and PI dyes, in order to evaluate the nuclear morphology (DNA condensation and fragmentation), to assess 
apoptotic cell death, and plasma membrane integrity, to assess the number of necrotic cells (by fluorescence microscopy). 
The basal levels of cell viability were also assessed in untreated cells (A). Cell viability, necrosis and apoptosis were 
expressed as a percentage of the total number of cells. A) Mutant cells presented decreased cell viability and increased 
levels of apoptosis. B and C) Treatment with ALCAR and DCA showed little effect in wild-type cells, whereas in mutant 
cells, the higher concentrations of both compounds significantly increased cell viability, by decreasing the number of 
apoptotic cells. Results were expressed as mean ± SEM of 2 experiments (performed in triplicates or quadruplicates). 
Statistical analysis was performed by one-way ANOVA, ∗p < 0.05, ∗∗p < 0.01 or∗∗∗p < 0.001, relatively to the control. 
 
Our group has recently shown that ROS levels are increased in striatal mutant cells (Ribeiro 
et al., unpublished data), which was confirmed in our conditions (Figure 12). Indeed, 
mutant cells show a great capacity of oxidizing DCFH2 to DCF, demonstrating the presence 
of increased levels of ROS. We further assessed the effect of ALCAR and DCA on ROS 
production, in wild-type and mutant cells. ALCAR (0.1-0.5 mM) did not affect ROS 
production, whereas at the highest concentration (5 mM) an increase in ROS levels was 
observed (Figure 12B). On the other hand, 3 mM DCA (Figure 12A) was able to 
completely rescue ROS observed in mutant cells, down to wild-type levels. 
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Figure 12 - STHdhQ111/Q111 cells show increased ROS production, which is prevented by DCA. ROS levels are 
increased in mutant cells in basal conditions. A) DCA (3 mM) decreased this abnormal ROS production to wild-type 
control levels. B) ALCAR did not present any effect in decreasing the higher levels of ROS present in mutant cells. 
ALCAR (5 mM) increased even more the ROS levels in mutant cells. Results were expressed as mean ± S.E.M. from 3 
independent experiments (performed in triplicate). Statistical analysis was performed by two-way ANOVA, followed by 
Bonferroni post test. ***p < 0.001 when compared to the respective wild-type, and ###p < 0.001 when compared to 
control (untreated) condition. The wild-type 100% was 3.67x106 ± 0.7x106 RFU/min/mg protein. 
 
3.1.3.DCA and ALCAR cytoprotection suggests a role of PDH 
in HD abnormalities 
As previously mentioned, DCA is known to increase the activity of PDH (Fouque et al., 
2003). Thus, a protective effect of DCA on the abnormalities present in HD mutant cells, 
would suggest a role for the PDH in the disease.  
To assess if DCA or ALCAR affected PDH activity in our model, we evaluated the effect 
of a 24 h incubation with these compounds in PDH enzymatic activity (Figure 13A). We 
observed that incubation with 1 mM DCA did not affect PDH activity, whereas at 3 mM 
DCA, PDH activity significantly increased in mutant cells. In addition, ALCAR (500 μM) 
showed a tendency to decrease PDH activity in both wild-type and mutant cells. 
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Figure 13 - DCA and ALCAR affect PDH activity. A) The cells were incubated for 24 h with 1 mM and 3 mM DCA 
and 500 μM ALCAR, and PDH activity was measured as described in Material and Methods. One millimolar DCA had no 
relevant effect in PDH activity, whereas 3 mM DCA showed a tendency to increase PDH activity in mutant cells, as 
expected, although it seemed to have the opposite effect in wild-type cells. ALCAR (500 µM) also showed a tendency to 
decrease PDH activity, in both wild-type and mutant cells.  B and C) Schematic representation of the mechanism of 
action of DCA (B) and ALCAR (C). DCA is a pyruvate analog that inhibits the activity of PDH kinase (PDK), which, in 
turn, phosphorylates PDH E1alpha subunit, inhibiting PDH activity. ALCAR facilitates the transport of acetyl groups 
across the mitochondrial inner membrane, increasing the amount of acetyl-coenzyme A available. Results were expressed 
as mean ± SEM of 3 experiments (performed in triplicate). The wild-type 100% corresponds to 1178.00 ± 247.00 
AU/min/mg protein (A). Statistical analysis was performed by two-way ANOVA followed by Bonferroni post 
test: ∗p < 0.05, relatively to the respective wild-type., or by t-test: ttp<0.01, relatively to the respective untreated control. 
3.2. DISCUSSION 
Mitochondrial dysfunction and apoptosis have been implicated in the neuronal cell death 
observed in HD (e.g. Gil and Rego, 2008). Mitochondrial deficits are, among other things, 
related to altered NADH/NAD
+
 levels and PDH activity (Ferreira et al., 2011). This 
evidence of altered PDH homeostasis has been previously reported in several models of HD 
(Sorbi et al., 1983; Perluigi et al., 2005; Ferreira et al., 2011). In this work, we showed that 
a decrease in PDH function is also present in striatal STHdh
Q111/Q111
 cells (compared to 
STHdh
Q7/Q7
 cells). We observed a decrease in PDH activity in mutant cells, probably due to 
the higher levels of phosphorylation observed in the three regulatory serines (232, 293 and 
300) of the E1alpha subunit of PDH, and also to the decreased protein levels of the PDH 
subunit E1alpha. Similar findings were previously described by our group in HD cybrids 
(Ferreira et al., 2011) retaining a tendency for more pronounced phosphorylation at Ser 232. 
This residue is only phosphorylated by the isoform 1 of PDK and, among the three, it is the 
second to be preferentially dephosphorylated by PDPs (Rardin et al., 2009a). This suggests 
a role in the mechanisms responsible for phosphorylation/dephosphorylation of this serine. 
The observed higher levels of phosphorylation are in agreement with the lower activity of 
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PDH in this model, as the phosphorylation of any of the three residues leads to the 
inhibition of the PDH activity (Rardin et al., 2009a). We also observed a decrease in the 
protein levels of the E1alpha subunit that might be due to alterations in protein expression 
(Perluigi et al., 2005), in response to a possible alteration of some transcription factors 
known to regulate PDH, like PGC-1α, which is known to be altered in HD, and specifically 
in STHdh
Q111/Q111
 cells (Cui et al., 2006; Kiilerich et al., 2010).  
HD is characterized by striatal neuronal cell death (Gil and Rego, 2008). Thus, a decrease 
in cell viability is expected in striatal HD cell models. Indeed, in striatal STHdh
Q111/Q111
 
cells, we observed a decrease in cell viability, along with an increase in apoptosis and 
necrosis. The increase in apoptotic cells, together with the increased ROS levels was 
expected in mutant cells, in accordance with data previously reported in HD cybrids 
(Ferreira et al., 2011). The same was also observed by Rosenstock et al. (2011) in 
STHdh
Q111/Q111
 cells, that exhibited features of mitochondrial-driven apoptosis, but not 
DNA fragmentation/condensation (Rosenstock et al., 2011). With this in mind, and taking 
into account that mitochondria plays a central role in HD pathology, we identified the 
changes in PDH in these cells. The central role of PDH in cellular bioenergetics makes it a 
suitable target when trying to revert the bioenergetics changes that have been described in 
HD (e.g. Gil and Rego, 2008). In this study, we used two compounds known to ameliorate 
other pathologies related with deficient PDH activity: ALCAR and DCA. ALCAR has the 
capacity to translocate through the inner mitochondrial membrane, being then converted 
into acetyl-CoA by carnitine acyl transferases (Jones et al., 2010). DCA acts differently, by 
increasing PDH activity through decreased activity of its kinase (PDK) and the turnover of 
the PDH E1alpha subunit (Morten et al., 1998; Fouque et al., 2003). The evidence that both 
compounds are able to increase cell viability and decrease apoptosis in mutant cells 
suggests that altered mitochondrial bioenergetics plays an important role in the neuronal 
cell death in HD. Importantly, the ability of DCA (3 mM) to almost completely restore low 
levels of ROS in mutant cells, suggests that PDH might be a central player in HD pathology. 
Indeed, the efficacy of DCA in increasing PDH activity in mutant cells, suggests that the 
higher ROS production observed in these cells might also be related to lower levels of 
NADH/NAD
+
 directly related with PDH deficiency (since PDH activity produces NADH) 
(Ferreira et al., 2011). In fact, if the ROS production in mutant cells is due to failure of the 
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OXPHOS, it is expectable that amelioration in PDH activity reflects into a decrease in ROS 
levels. The tendency for a decrease in wild-type PDH activity after exposure to DCA (3 
mM) might be due to a long term regulation of PDH by the end-product of the reaction 
(Behal et al., 1993). Han et al. have also shown that 24 h exposure to 5 mM DCA led to an 
increase in PDH activity (Han et al., 2008). Rardin et al. tested the same concentration of 
DCA (5 mM), but only for 2 h, observing that, after that time, there was a significant 
decrease in PDH phosphorylation, that was correlated with an increase in PDH activity 
(Rardin et al., 2009b). Also, the decrease in PDH activity in the presence of ALCAR was 
expectable, due to PDH end-product inhibition caused by the higher levels of AcetylCoA. 
Furthermore, the fact that ALCAR did not show any effect in ROS levels suggests that the 
mechanisms mostly responsible for ROS production may be localized upstream the Krebs 
cycle. Also, the activity of the Krebs cycle enzyme α-ketoglutarate dehydrogenase was 
shown to be increased in HD cybrids (Ferreira et al., 2011) and to be related with ROS 
production, depending on the NADH/NAD
+
 ratio (Tretter and Adam-Vizi, 2004). Thus, 
supplying the Krebs cycle with its starting molecule is not expected to decrease ROS 
production.  
In summary, in this chapter, we confirmed that, in comparison with wild type cells, striatal 
STHdh
Q111/Q111
 cells have higher ROS production, PDH phosphorylation, apoptosis and 
necrosis, and lower cell viability, PDH activity and E1alpha protein levels. Also, the 
protective effect of DCA, a compound that increases PDH activity, in ROS production and 
cell viability suggests a central role of this enzyme in HD cellular alterations. 
  
 
 
CHAPTER 4 –  
INSULIN AND IGF-1 IN BIOENERGETIC 
DEFICITS  
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Insulin and insulin-like growth factors (IGFs) -1 and -2 have been shown to exert 
neuroactive and protective effects (Dudek et al., 1997). Our lab has recently described a 
protective effect of IGF-1 against some peripheral diabetic features of HD (Duarte et al., 
2011). In addition, IGF-1/Akt pathway was shown to be a suitable target in HD 
neuroprotection (Humbert et al., 2002). Because of their implications in neuronal health, in 
this chapter we will explore both insulin and IGF-1 in HD neuroprotection, focusing on 
bioenergetics dysfunction involving PDH.  
4.1. RESULTS 
4.1.1.Insulin/IGF-1 do not affect ATP/ADP but alters PCr 
levels 
STHdh
Q111/Q111
 cells were previously shown to present lower levels of ATP/ADP ratio 
when compared to wild-type cells (Gines et al., 2003). A tendency for decreased ATP 
levels in HD cybrids was also reported by Ferreira et al (2011). Moreover, reduced 
PCr/inorganic phosphate was found in resting muscle of HD patients (Lodi et al., 2000). 
However, more recently, PCr was found to be increased in three HD mouse models,  R6/2 
mice, N171-82Q and Hdh
Q111/Q111 
mice (Zhang et al., 2011). Importantly, the 
STHdh
Q111/Q111
 cell line used in the present study was obtained from the immortalization of 
striatal cells of Hdh
Q111/Q111 
mice.  
In this mutant cell line, we examined the occurrence of ATP/ADP (Figure 14A) and PCr 
(Figure 14B) abnormalities, and thus tested the effect of 0.1 nM insulin and 1 nM IGF-1 in 
both parameters. These concentrations were selected based on the lower concentrations (in 
the range of the receptor selectivity-window) that protected STHdh
Q111/Q111 
cells against 
ROS production (data not shown). The ATP/ADP ratio was found to be decreased in 
mutant striatal cells, when compared to wild-type cells; however, none of the proteins, 
insulin or IGF-1, affected the ATP/ADP ratio in these cells (Figure 14A). In contrast, PCr 
levels were found to be dramatically increased in mutant cells, and both insulin and IGF-1 
partially but significantly restored these levels (Figure 14B). 
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Figure 14 - ATP/ADP ratio and PCr levels are altered in STHdh Q111/Q111 cells. Cells were incubated for 24h with 0.1 
nM insulin or 1 nM IGF-1 and ATP, ADP and PCr levels were assessed as referred in Material and Methods. A) Mutant 
cells showed decreased ATP/ADP levels, which were not significantly affected by insulin or IGF-1. B) PCr levels were 
increased in mutant cells when compared with wild-type cells, and the presence of insulin or IGF-1 significantly reduced 
these levels. Results were expressed as mean ± S.E.M. from 3 independent experiments. Statistical analysis was 
performed by two-way ANOVA, followed by Bonferroni post test. *p < 0.05, **p < 0.01 and ***p < 0.001 when 
compared to wild-type cells and ##p < 0.01 when compared to the respective control (untreated) condition. The wild-type 
100% corresponds to 21.41 ± 3.16 (A) and 0.08 ± 0.01 pmol/mg protein (B). 
4.1.2.Insulin/IGF-1 do not significantly affect lactate/pyruvate 
levels 
Ferreira et al. recently found increased levels of lactate/pyruvate in HD cybrids (Ferreira et 
al., 2011). In contrast, in STHdh
Q111/Q111
 cells, we observed a significant decrease in 
lactate/pyruvate ratio, when compared to STHdh
Q7/Q7
 cells (Figure 15C). Insulin (0.1 nM) 
did not affect these levels. However, IGF-1 (1 nM) slightly, but significantly, increased 
lactate/pyruvate in wild-type cells, although it had no significant effect in mutant cells. 
Lactate levels were found to be similar in wild-type and mutant cells (Figure 15A), whereas 
pyruvate levels were largely increased in mutant cells (Figure 15B). IGF-1 (1 nM) 
significantly and partially decreased pyruvate levels in mutant cells. However, as 
previously mentioned, this decrease in pyruvate in the presence of IGF-1 was not 
accompanied by an increase in lactate/pyruvate levels, probably due to a slight decrease in 
lactate levels in the same conditions (Figure 15A).  
In mitochondria, pyruvate can be used by PDH to produce acetyl-CoA; in the cytosol, 
pyruvate can be used by lactate dehydrogenase (LDH) to produce lactate (Figure 15D). So, 
in order to understand the mechanisms underlying pyruvate accumulation in mutant cells, 
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and a possible protection by insulin/IGF-1, we studied LDH activity (Figure 16) and PDH 
activity and expression (Figure 17).  
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Figure 15 - Pyruvate levels and lactate/pyruvate ratio are altered in STHdh Q111/Q111 cells, whereas lactate levels are 
not affected. Cells were incubated for 24 h with 0.1 nM insulin or 1 nM IGF-1, and lactate and pyruvate levels were 
calculated as described in Material and Methods. A) Lactate levels show no alteration between wild-type and mutant cells. 
B) Pyruvate levels were significantly increased in mutant cells when compared to wild-type cells and 1 nM IGF-1 slightly 
reduced those levels. C) Lactate/pyruvate ratio was decreased in mutant cells and neither insulin nor IGF-1 exerted any 
protection. D) Schematic representation of the cellular relation between pyruvate and lactate. Results are expressed as the 
mean ± S.E.M. from 3 independent experiments. Statistical analysis was performed by two-way ANOVA, followed by 
Bonferroni post test. ***p < 0.001 when compared to wild-type cells and #p < 0.05, ###p < 0.001 when compared to the 
respective control (untreated) condition. The wild-type 100% corresponds to 14.25 ± 1.27 AU/mg protein (A) and 
86412,00 ± 11806,00 RFU/mg protein (B). 
4.1.3.Insulin/IGF-1 normalize LDH activity in STHdh
Q111/Q111
 
cells without affecting PDH 
The results described above suggest that LDH activity might be altered in HD cells. Indeed, 
we found a significant decrease in LDH activity in untreated mutant cells (Figure 16). 
Interestingly, insulin (0.1 nM), in particular, and IGF-1 (1 nM) partially recovered LDH 
activity to wild-type levels.  
Pyruvate 
Lactate 
 NADH 
NAD+ 
LDH 
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Figure 16 - Lactate dehydrogenase activity is decreased in mutant cells and is partially recovered by both insulin 
and IGF-1. Mutant and wild-type cells were pre-incubated for 24 h with 0.1 nM insulin and 1 nM IGF-1, and LDH 
activity was calculated as described in the Material and Methods section. Basal levels of LDH activity were found to be 
decreased in mutant cells and exposure to 0.1 nM insulin seemed to recover this abnormality. Exposure to IGF-1 showed a 
tendency to decrease LDH activity also in wild-type cells, although not statistically significant. Results are expressed as 
mean ± S.E.M. from 3 independent experiments (performed in duplicate). Statistical analysis was performed by two-way 
ANOVA, followed by Bonferroni post test. *p < 0.05 when compared to wild-type cells. The wild-type 100% corresponds 
to 5.12 ± 0.98 mol/s/mg protein. 
 
Another explanation for the higher levels of pyruvate in mutant cells could be the abnormal 
activity and phosphorylation (inactivation) of PDH, as previously described (Chapter 3, 
Figure 10B,C). Previously, Gottschalk et al. (1991) showed that insulin can regulate PDH 
activity (Gottschalk, 1991). Thus, we tested to restore the normal levels of PDH activity 
and phosphorylation using both insulin and IGF-1. However, insulin (0.1 nM) and IGF-1 (1 
nM) did not recover PDH activity in mutant cells (Figure 17A). Indeed, insulin (0.1 nM) 
slightly decreased PDH activity levels in mutant cells. On the other hand, IGF-1 (1 nM) 
affected PDH activity in wild-type levels. The effect of insulin and IGF-1 on PDH E1alpha 
subunit levels and phosphorylation were assessed using a colorimetric kit (Figure 17B,C). 
Neither insulin (0.1 mM) nor IGF-1 (1 nM) affected the levels of PDH E1alpha subunit in 
mutant cells (Figure 17B). However, IGF-1 (1 nM) significantly decreased the levels of PDH 
E1alpha levels in wild-type cells. In addition, none of the two proteins (insulin or IGF-1) 
restored PDH phosphorylation levels in mutant cells (Figure 17). However, insulin (0.1 nM) 
seemed to decrease the difference in Ser232 phosphorylation, between wild-type and 
mutant cells. Similarly, both insulin and IGF-1 showed a tendency to partially restore the 
phosphorylation of serines 293 and 300 in mutant cells. However, in all cases, the levels of 
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phosphorylation observed in the mutant cells were still extremely higher than in wild-type 
cells. 
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Figure 17 - PDH in mutant cells presents abnormal protein levels, phosphorylation and activity that are not 
restored by insulin or IGF-1. PDH activity was measured from total extracts of wild-type and mutant cells, as referred in 
Material and Methods. The protein expression levels and the phosphorylation of PDH E1alpha subunit were assessed 
using a kit, as described in Materials and Methods. In both cases, some cells were previously incubated for 24 h with 0.1 
nM insulin or 1 nM IGF-1. A) PDH activity was decreased in mutant cells and neither insulin nor IGF-1 exposure affected 
those levels. Total PDH E1alpha expression (B) and phosphorylated forms at Ser 232, Ser293 or Ser 300 (C) were 
analyzed in wild-type and mutant cells. Mutant cells showed decreased levels of PDH E1alpha subunit, whereas 
phosphorylation of these three serines was increased. Insulin and IGF-1 did not change this condition. Results were 
expressed as the mean ± S.E.M. from 3 independent experiments (performed in duplicate). Statistical analysis was 
performed by two-way ANOVA, followed by Bonferroni post test. *p < 0.05, **p < 0.01 and ***p < 0.001 when 
compared to wild-type cells and ##p < 0.01 when compared to the respective control (untreated) condition. Janus Green, 
phosphorylated form/ total PDH E1alpha or PDH activity (slope)/protein concentration. For each graph the wild-type 100% 
was 1178.00 ± 247.00 AU/min/mg protein (A), 3.60 ± 0.98 (B), 4.32 ± 1.42 for pSer 232 (C), 3.94 ± 1.16 for pSer 293 (C) 
and 3.28  ± 0.62 for pSer 300 (C). 
4.2. DISCUSSION 
Among all the cellular alterations observed in HD, mitochondrial alterations and, 
consequently, bioenergetic deficits, are amongst the best candidates to be responsible for 
neuronal cell death (e.g. Gil and Rego, 2008; Ferreira et al., 2011). Thus, any compound 
that can overcome these bioenergetics problems would be of great value in the treatment of 
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this disease. Insulin and IGF-1 are well-known for stimulating glucose uptake and 
intracellular metabolism in peripheral tissues. The role of these polypeptides in the brain is 
less defined; however, they have been described as having neurotrophic, neuromodulator 
and neuroendocrine functions (Lynch et al., 2001; Andreassen et al., 2002; Gerozissis, 
2004).  
ATP/ADP deficits described in the present and in previous (Gines et al., 2003; Seong et al., 
2005) reports, are well known characteristics of some HD models. ATP levels are 
controlled by energy-producing and consuming processes (Oláh et al., 2008). The observed 
decrease in ATP/ADP ratio might be due to a decrease in ATP levels when compared to 
ADP, meaning that either ATP is being less produced, or more consumed. Indeed, lower 
ATP production was previously reported in HD models (Milakovic and Johnson, 2005; Ryu 
et al., 2005). We also found that PCr levels are highly increased in mutant cells, in 
accordance with the study of Mochel et al. ( 2012) in the striatum of the STHdh
Q111/Q111 
mice, which suggests that this indirect source of ATP may not be accessible, and thus not 
compensating the lack of ATP. Thus, impairment in PCr utilization in mutant cells may 
contribute to increase ATP utilization, leading to a decrease in ATP/ADP. Since insulin and 
IGF-1 pathways are known to be related with glucose uptake (Frick et al., 2000), 
hypothetically, both proteins could compensate the lack of ATP observed in STHdh
Q111/Q111
 
cells by increasing glucose metabolism. However, no significant difference was observed in 
ATP/ADP ratio in the presence of insulin or IGF-1. Also, the lack of effect of insulin and 
IGF-1 on PCr levels suggests a failure of both neurotrophic factors in fighting the 
bioenergetic problems observed in these cells. Nevertheless, a small, but significant, 
decrease in PCr levels was observed. 
Since these results suggested glycolytic abnormalities in mutant cells, we investigated the 
levels of lactate and pyruvate. Previously, Ferreira et al. (2011) described an increase in 
lactate/pyruvate levels in HD cybrids (Ferreira et al., 2011). The same was observed in the 
cortex of HD patients (Koroshetz et al., 1997; Martin et al., 2007) and in R6/2 mice brains 
(Tsang et al., 2006). However, ours and Hoang et al. (1998) data in HD patients found no 
differences in lactate levels. In STHdh
Q111/Q111
 cells one of the greatest problems seems to 
be the high accumulation of pyruvate, suggesting deficits in the mechanism that usually 
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uses it (the transformation into lactate or into acetyl-CoA, by LDH or PDH, respectively, or 
the into alanine, by alanine transaminase) and most probably not in the mechanisms that 
produce it via glycolysis; nevertheless, we cannot exclude the possibility of altered 
glycolysis regulation. Interestingly IGF-1 (1 nM) slightly reduced pyruvate levels in mutant 
cells, but, apparently, not by restoring lactate/pyruvate ratio, since neither insulin nor IGF-1 
had any effect in this parameter.  
The lack of inter-conversion of the excess pyruvate into lactate reveals metabolic 
dysfunction. Thus, we next evaluated the activities of both enzymes that could be 
responsible for using the high pyruvate levels, PDH and LDH. The decreased PDH activity 
observed in STHdh
Q111/Q111
 cells may justify the high levels of pyruvate observed. However, 
insulin and IGF-1 were unable to change PDH activity or E1alpha subunit levels and 
phosphorylation. This suggests that the decrease in pyruvate levels observed in the presence 
of IGF-1 was not due to an increase in its oxidation into Acetyl-CoA. However, in RAT 1 
embryonic fibroblasts and Chinese hamster ovary (CHO) cells, insulin was shown to 
increase PDH activity (Gottschalk, 1991). On the other hand, and as hypothesized, LDH 
activity decreased in STHdh
Q111/Q111
 cells. This difference was nulled by the presence of 
both insulin and IGF-1. Thus, we expected that the levels of lactate would also increase, 
which was not observed. A possible explanation for this lack of concordance could be a 
divertion of pyruvate into alanine metabolism by alanine transaminase. 
In summary, in this chapter we characterized some bioenergetics alterations of 
STHdh
Q111/Q111
 cells, including decreased ATP/ADP ratio, lactate/pyruvate ratio, LDH and 
PDH activities, and increased PCr and pyruvate levels. However the neurotrophic factors 
insulin and IGF-1 did not significantly affect those bioenergetic changes. Despite these 
findings, we observed a promising effect of IGF-1 (1 nM) in restoring the decrease in LDH 
activity and slightly reducing the high levels of pyruvate in mutant striatal cells. 
  
 
CHAPTER 5 –  
IHDACS IN PDH DYSFUNCTION 
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HD is characterized by the expression of mHtt, which  has been described to interfere with 
nuclear transcription factors and cofactors, leading to transcriptional deregulation (Zhai et 
al., 2005; Benn et al., 2008). Among the genes affected in HD there are several genes 
linked to mitochondrial function (e.g. Cui et al., 2006). Thus, in this work, we used 
iHDACs, as an attempt to overpass the transcriptional deregulation observed in HD.  
Histone acetylation, performed by HATs is known to favor gene transcription (Struhl, 
1998). On the other hand, HDACs repress gene expression (Struhl, 1998), as does mHtt. 
Thus, iHDACs could compensate the gene repression provoked by mHtt. In this work, we 
used the well-known iHDACs TSA, PB and SB, previously shown, by our group, to 
ameliorate Ca
2+
-handling in HD models (Oliveira et al., 2006). 
5.1. RESULTS 
5.1.1. iHDACs protect STHdhQ111/Q111 cells 
First, we evaluated the effect of the iHDACs in cell viability. Mutant and wild-type cells 
were incubated, for 24 h, with different concentrations of the iHDACs: 10, 50 and 100 nM 
TSA; and 100, 250 and 500 μM PB or SB. Cells were further labeled with Hoechst and PI 
fluorescent dyes in order to analyze the nuclear morphology and evaluate apoptotic and 
necrotic cell death (Figure 18C). Wild-type cells showed no significant difference in the 
percentage of necrotic and apoptotic cells, when exposed to any concentration of PB or SB 
(Figure 18A). Only 100 nM TSA induced a significant decrease in the number of viable 
cells, along with an increase in apoptotic cells, whereas 50 nM TSA caused a slight, but 
significant, decrease in the number of viable cells. On the other hand, mutant cells, which 
presented lower viability compared to wild-type (STHdh
Q7/Q7
) cells, seemed to benefit from 
the presence of the iHDACs (Figure 18B). All the concentrations of PB and SB used 
induced a significant increase in the percentage of viable mutant cells, together with a 
decrease in apoptotic cells (except 100 μM PB, which did not significantly affect apoptosis). 
TSA, at 10 nM only, showed beneficial effects over mutant cell viability. 
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Figure 18 - All of the iHDACs tested increased mutant cell viability. After 24 h incubation with different 
concentrations of TSA, PB and SB, wild-type (A) and mutant (B) cells were stained with Hoechst and PI fluorescent dyes, 
in order to evaluate apoptotic cell death by following the nuclear morphology (DNA condensation and fragmentation) and 
plasma membrane integrity (to assess the number of necrotic cells), by fluorescence microscopy. A) Wild-type cells were 
not negatively affected by the presence of PB or SB. However 100 nM TSA significantly decreased the percentage of 
viable cells, mainly by increasing the amount of apoptotic cells. B) Mutant cells, which showed low cell viability in basal 
conditions (CTR), seemed to be positively affected by PB and SB (100-500 µM), and by TSA (10 nM). C) Representative 
microscopy images used to assess cell viability. Nuclei were labeled with Hoechst (blue) and PI (red blots). Results were 
expressed as mean ± S.E.M. from 2 independent experiments (performed in quadruplicate). Statistical analysis was 
performed by one-way ANOVA, followed by Bonferroni post test. *p < 0.05, **p < 0.01 and ***p < 0.001 when 
compared to the respective control. 
5.1.2. TSA, PB and SB increase histone H3 acetylation 
In order to confirm the effects of the iHDACs on the acetylation of nuclear histones, we 
evaluated (by western blotting) the levels of acetylated histone 3 (H3) in wild-type and 
mutant cells (Figure 19). TSA (at 100 nM) significantly increased H3 acetylation in both 
wild-type (Figure 19A) and mutant cells (Figure 19D). Both 10 nM and 50 nM TSA 
showed a tendency to increase H3 acetylation, although not statistically significant. PB 
(Figure 19B,E) and SB (Figure 19C,F), both showed the maximum effect at 500 μM. SB 
(250 µM) significantly increased the acetylation of H3, in wild-type cells (Figure 19C). SB 
(100 μM) also induced a notable increase in H3 acetylation (Figure 19C), although not 
significant. Visible increased H3 acetylation can be detected in each one of the 
representative blots. 
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Figure 19 - iHDACs increase the acetylation of histone 3 (H3). Wild-type and mutant cells were incubated for 24 h 
with different concentrations of iHDACs, and total extracts and western blots were performed as described in Material and 
Methods. Wild-type (A) and mutant (D) cells exposed to 100 nM TSA showed a significant increase in H3 acetylation. 
TSA (50 nM) slightly increased H3 acetylation in mutant cells. Exposure to 500 μM PB (B and E) also increased the H3 
acetylation (more significantly in wild-type cells). SB (500 µM) increased the H3 acetylation in both wild-type (C) and 
mutant (F) cells, and at 250 μM, it also increased H3 acetylation in wild-type cells. Results were expressed as 
mean ± S.E.M. from 5-8 independent experiments. Statistical analysis was performed by one-way ANOVA, followed by 
Bonferroni post test. *p < 0.05, **p < 0.01 and ***p < 0.001 when compared to the respective control. 
5.1.3. SB and PB increase PDH levels and decreased PDH 
phosphorylation in STHdh
Q111/Q111
 cells 
As referred before (Chapter 3) PDH seems to play a central role in the bioenergetics 
deficits associated with HD. Thus, our next step was to evaluate the effect of the iHDACs 
in the activity (Figure 20A), protein levels of E1alpha subunit (Figure 20B,C) and 
phosphorylation (Figure 20D,E) of PDH. We did not use 100 nM TSA in this experiment 
due to the observed decrease in wild-type cell viability and lack of protection in mutant 
cells. Accordingly, we used 10 nM and 50 nM TSA, which showed a strong tendency to 
increase H3 acetylation in both mutant and wild-type cells, although not statistically 
significant. PDH activity was not affected by any iHDAC in mutant cells (Figure 20A), 
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although more experiments should be performed given the great variability in these results. 
In wild-type cells, 10 nM TSA and 500 µM PB increased the protein levels of the E1alpha 
subunit (Figure 20B). In turn, 250 µM PB and 500 µM SB increased E1alpha PDH subunit 
levels in mutant cells (Figure 20C). In wild type cells, PDH E1alpha phosphorylation at 
serine 232 decreased (linked to PDH activation) in the presence of PB (250 and 500 µM) 
(Figure 20D). Also, 500 µM PB significantly decreased PDH E1alpha phosphorylation at 
serine 293, whereas 250 µM PB increased its phosphorylation at serine 300. Importantly, in 
mutant cells, 500 µM SB seemed to be the most efficient condition at decreasing the 
phosphorylation at all the three serines (Figure 20E), showing a significant effect at serines 
293 and 300, and a strong tendency to decrease serine 232 phosphorylation. 
Phosphorylation of serine 293 was also decreased in the presence of 250 µM PB in mutant 
cells. In contrast, 10 nM TSA increased serine 232 phosphorylation in these cells (Figure 
20E). 
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Figure 20 - iHDACs do not affect PDH activity but can change total PDH levels and phosphorylation. PDH activity 
was measured from total extracts of wild-type and mutant cells, as referred in Material and Methods. The protein 
expression levels and the phosphorylation of PDH subunit E1alpha were assessed using a kit, as described in Materials 
and Methods. In both cases, cells were previously incubated for 24 h with different concentrations of iHDACs. A) None 
of the iHDACs tested showed beneficial effects in PDH activity, in mutant cells. Indeed, exposure to most iHDAC 
seemed to decrease PDH activity in wild-type cells. B) The levels of PDH in wild-type cells were significantly increased 
by 10 nM TSA and 500 μM PB. In mutant cells, 250 μM PB and 500 μM SB increased the levels of PDH (C). Serine 
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phosphorylation of PDH E1alpha in wild-type cells was decreased after exposure to 500 μM PB (at serines 232 and 293), 
and 250 μM of PB (at serine 232) (D). Mutant cells showed significant decrease in phosphorylation of serines 293 and 
300 when exposed to 500 μM SB. SB (250 µM) also decreased the levels of serines 293 and 300 phosphorylation (E). 
Results were expressed as mean ± S.E.M. from 3-5 independent experiments (performed in duplicate or triplicate). 
Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. *p < 0.05, **p < 0.01 and 
***p < 0.001 when compared to wild-type cells and ##p < 0.05 when compared to the respective control (A), and by one-
way ANOVA, followed by Bonferroni post test. *p < 0.05, **p < 0.01 and ***p < 0.001 when compared to the respective 
control (B, C, D, E). For each graph the wild-type 100% was 1178.00 ± 247.00 AU/min/mg protein (A), 1.96 ± 0.96 (B), 
7.99 ± 2.33 for pSer 232 (D), 4.67 ± 1.33 for pSer 293 (D) and 3.31  ± 1.12 for pSer 300 (D). The 100% mutant control 
corresponds to 6.01 ± 1.93 (C), 2.85 ± 0.93 for pSer 232 (E), 3.34 ± 2.32 for pSer 293 (E) and 2.00 ± 1.35 for pSer 300 
(E). 
5.1.4. SB apparently does not affect PDH kinase (PDK) and 
PDH phosphatase (PDP) protein levels 
PDH phosphorylation is catalyzed by one of four PDK isoforms. In opposition to the four 
PDKs, there are two isoforms of PDPs (PDP1 and PDP2) present in mammalian cells 
(Rardin et al., 2009a). As previously described, 500 μM SB decreased PDH 
phosphorylation in mutant cells in all serine residues tested; therefore, we next assessed its 
effect in the levels of the PDK1 (the only PDK that phosphorylates Ser232) and PDP1 
(mostly detected in brain and the most active PDP isoform) (Patel and Korotchkina, 2006) 
(Figure 21A,B – preliminary data). PDK1 showed a tendency to increase in mutant cells 
(Figure 21A). Also, PDP1 showed a tendency to decrease in mutant cells (Figure 21B). In 
both cases, 500 μM SB did not seem to affect PDK or PDP levels. 
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Figure 21 - Protein levels of PDK1 and PDP1 in wild-type and mutant cells. Wild-type and mutant cells were 
incubated for 24 h with 500 μM PB, and total extracts and western blotting were performed as described in Material and 
Methods. A) PDK protein levels showed a tendency to increase in mutant cells and the presence of SB did not revert this 
tendency. B) PDP protein levels showed a tendency to decrease in mutant cells, and was not affected by SB. Results were 
expressed as mean ± S.E.M. from 3 independent experiments. 
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5.2. DISCUSSION 
Transcriptional deregulation is a well-known characteristic of HD (reviewed in Gil and 
Rego, 2008), although the genes implicated and the degree by which they are affected are 
still a matter of study. Mitochondrial gene expression is regulated in the nucleus by the 
transcriptional co-activator PGC-1alpha (Lin et al., 2004, 2005). Thus, it is easy to 
understand that altered PGC-1alpha function results in significant mitochondrial 
impairment (Kim et al., 2010). Indeed, PGC-1alpha levels were found to be reduced in HD 
(Cui et al., 2006), linking the transcriptional deregulation to the mitochondrial problems 
observed in HD. PGC-1alpha transcription, in turn, is regulated by CREB (Cui et al., 2006), 
which was shown to be directly affected by mHtt (Steffan et al., 2000). A way to try to 
overpass this problem is to increase gene transcription. Acetylation of histones is known to 
increase gene expression by increasing DNA accessibility to the transcriptional machinery 
(Unnikrishnan et al., 2010). Since histone acetylation is catalyzed by HATs and removed 
by HDACs (Rice and Allis, 2001), the use iHDACs could be a way to increase the 
transcription of genes downregulated in the presence of mHtt.  
In this work, we showed that exposure to three iHDACs (TSA, PB and SB) increased the 
viability of STHdh
Q111/Q111
 cells, by increasing the number of viable cells and decreasing 
the number of apoptotic cells. These findings suggest that the decreased gene expression in 
HD is linked to the neuronal death observed in this disease. Indeed, the decreased 
expression of the transcriptional co-activator PGC-1alpha, suggested that STHdh
Q111/Q111
 
cells also share this deregulation of gene expression (Cui et al., 2006). The effect of the 
iHDACs is supported by the significant increase in H3 acetylation achieved with the 
highest concentrations of iHDACs. However, considering the vast effects of the iHDACs 
throughout the genome, it turns out difficult to determine which are the most important 
genes that are expressed in order to increase cell viability. iHDACs were previously shown 
to ameliorate axonal transport in HD cells (Dompierre et al., 2007) and the 
neurodegenerative phenotype in HD mice (Ferrante et al., 2003). Steffan et al. (2001) 
showed that iHDACs arrest ongoing progressive neuronal degeneration induced by polyQ 
repeat expansion, and reduce lethality in two Drosophila models of polyQ diseases (Steffan 
et al., 2001). In our group, Oliveira et al. (2006) showed that iHDACs increase Ca
2+
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handling in STHdh
Q111/Q111
 cells, which was linked to increased mitochondrial function. 
One of the mitochondrial abnormalities that seems to be linked with deficient bioenergetics, 
as described before, is the alteration in PDH activity. The decrease levels of the E1alpha 
subunit observed in STHdh
Q111/Q111
 cells suggested protein expression abnormalities, which 
was correlated with decreased PDH activity. Both PB (250 μM) and SB (500 μM) were 
able to increase the protein levels of the PDH E1alpha subunit in mutant cells, suggesting 
that PDH expression is basally affected in HD cells, and that the use of iHDACs could be a 
way to overcome this problem. In mutant cells, the phosphorylation of the E1alpha subunit 
was also significantly decreased in the serines 293 and 300 by SB (500 μM), along with a 
strong tendency for a decrease in serine 232 phosphorylation. Serine 293 phosphorylation 
was also decreased by PB (250 μM). This alteration in PDH phosphorylation suggests that 
maybe one of the two enzymes that regulate PDH phosphorylation (PDK and PDP) (Rardin 
et al., 2009a) was affected by iHDACs. This hypothesis is supported by the previous 
observation that TSA and PB lead to a decrease in the protein levels of the hypoxia-
inducible factor 1 (HIF-1) (Kim et al., 2007), known to be responsible for the expression of 
PDK1 (Kim et al., 2006; Kirito et al., 2009). However, SB (at 500 μM; the iHDAC at a 
concentration that proved to be most efficient at decreasing E1alpha phosphorylation), 
showed no significant effects on PDK1 or PDP1 levels, although these experiments need to 
be repeated. The apparent lack of effects might be due to the influence of SB on other 
isoforms of PDK and PDP. Moreover, the tendency for increased PDK and decreased PDP 
levels in mutant cells is in agreement with the increase in E1alpha phosphorylation 
observed in mutant cells. Despite the lack of alteration in PDK and PDP levels in the 
presence of SB, the lowering of the phosphorylation levels and the increase in the levels of 
the E1alpha PDH subunit may result in increased PDH activity. Moreover, PDH can be 
directly modulated by acetylation (at E2 subunit), leading to increased enzymatic activity 
(Behal et al., 1993). However, preliminary data showed that none of the iHDACs used were 
able to increase PDH activity in mutant cells, which may be due to insufficient alteration in 
phosphorylation in order to cause significant alterations in PDH activity. Therefore, further 
experiments will be required to conclude on the exact changes in PDK1 and PDP1 levels 
and PDH activity influenced by treatment with SB. 
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In summary, we showed that iHDACs have protective effects in HD striatal cells, by 
decreasing cell death by apoptosis, thereby increasing the number of viable cells. Also, SB 
(500 μM) was able to decrease phosphorylation and increase the levels of the E1alpha 
subunit in mutant cells. These data reveal that iHDACs, and particularly SB, as a promising 
therapeutic compounds to ameliorate mitochondrial dysfunction in HD. 
  
 
 
CHAPTER 6 –  
RHO-ZERO CREATION 
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As emphasized in the previous chapters, mitochondria play a central role in HD 
pathogenesis. In this work, we also approached the creation of rho-zero cells from 
lymphoblastoid cell lines of HD patients and healthy subjects. For this purpose, 
endogenous mtDNA was depleted by prolonged exposure of the cells to low concentrations 
of EtBr, which should selectively damage and inhibit mtDNA replication and transcription 
(King and Attardi, 1989). The experiments were initially performed as described in 
materials and methods section (see also Figure 9A), with the lymphoblastoid lines CTR 
5724 and HD 5678 exposed to EtBr (0, 50, 75, 100, 250 and 500 ng/ml). The experiment 
with the two highest concentrations was soon abandoned because none of the lines survived 
more than two weeks in those conditions (data not shown). Also, in the middle of the 
experiment, the cell line HD 5678 was found to be contaminated, so, all the results obtained 
with that line were discarded. The cell line CTR 5724 was exposed to 0, 50, 75 and 100 
ng/ml EtBr for 35 days, when a sample of cell suspension was collected to evaluate cell 
proliferation, morphology, and oxygen consumption. Additionally we performed 
experiments in the lymphoblastoid lines HD 5678, HD 5610, CTR 4800 and CTR 4808 
(Figure 9B). In this experiment we exposed the cells to 0, 50 and 75 ng/ml EtBr for 64 days. 
6.1. RESULTS 
6.1.1.EtBr exposure decreased lymphoblast proliferation and 
cell aggregate formation 
Lymphoblastoid cell lines normally grow in suspension, with cells clumped in loose 
aggregates, normally reaching the plateau level (about 1x10
6
 cells/ml) 4 to 5 days after 
seeding at 0.2 x 10
6
 cells/ml. Our results showed that cells exposed to EtBr exhibited 
decreased proliferation rate, when compared to untreated cells (Figure 22). Indeed, in 
agreement, EtBr-exposed cells were shown to be less prone to form aggregates, when 
compared to those cultured in the absence of EtBr (Figure 23). All the three concentrations 
of EtBr used decreased cell aggregation, when compared to untreated cells. Exposure to the 
higher concentration of EtBr (100 ng/ml) produced a drastic decrease in the cell 
aggregation. The presence of EtBr in the culture (4 days upon EtBr removal) was evidenced 
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by fluorescence microscopy (absorption at 482 nm (blue-green), emission at 616 nm (red-
orange)); in fact, a red labeling was observed within the cells (Figure 23). 
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Figure 22 - EtBr decreased lymphoblast proliferation. The cell line (CTR 5724) was cultured for 35 days in the 
absence or in the presence of different concentrations of EtBr (0, 50, 75 or 100 ng/ml), and then seeded at a density of 
0.3x106 cells/ml. At day 3, and until day 5, the cells were evaluated by trypan blue assay and counted by using an 
hemocytometer. The presence of any concentration of EtBr decreased the proliferation of the cells, when compared to the 
untreated control. Statistical analysis was performed by one-way ANOVA, followed by Bonferroni post test. #p < 0.05, 
##p < 0.01 and ###p < 0.001 when compared to control. 
 
 
Figure 23 –CTR 5724 cell line exposed to EtBr forms smaller aggregates. Lymphoblasts (cell line CTR 5724) were 
untreated (0 ng/ml EtBr) or treated with EtBr (50, 75 or 100 ng/ml) for 35 days and cell morphology was evaluated 4 days 
after EtBr removal, by fluorescent microscopy. The presence of EtBr in the culture is demonstrated by the red color. All 
the cells exposed to EtBr lost the capacity to form aggregates and evidence the presence of EtBr. The cells exposed to 100 
ng/ml EtBr show the most drastic loss of capacity to form healthy aggregates.  
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6.1.2.Time-dependent effect of EtBr exposure on oxygen 
consumption 
In order to check for rho-zero status (absence of O2 consumption), lymphoblasts cultured in 
the absence or in the presence of EtBr (50, 75 or 100 ng/ml) were tested for oxygen 
consumption. For this purpose, the oxygen consumption rate of the cell line CTR 5724, 
exposed for 35 days to EtBr (at 50 and 100 ng/ml), was evaluated 25 days after EtBr 
removal (see Figure 9A). Results depicted in Figure 24 show that 50 ng/ml EtBr did not 
affect and 75 ng/ml EtBr led to a small decrease in the oxygen consumption rate in these 
cells. Unfortunately, we were not able to assess the oxygen consumption rate of cells 
exposed to 100 ng/ml of EtBr, since a significant decrease in the proliferation rate occurred 
for this EtBr concentration, preventing the expansion of this cell line, in order to obtain a 
sufficient number of cells to perform this experiment. 
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Figure 24 - 35 days in EtBr are not enough to significantly reduce the oxygen consumption rate in the CTR 5724 
cell line. Lymphoblasts (cell line CTR 5724) were culture in the absence (0 ng/ml EtBr) or in the presence of EtBr (50 or 
75 ng/ml) for 35 days, and basal rate of O2 consumption was evaluated 25 days after EtBr removal. None of the EtBr 
concentrations were effective in decreasing the oxygen consumption in the conditions tested (that would be observed in a 
rho-zero phenotype). The control 100% corresponds to 19.24 nmol O2/ml/min/5 x 10
6 cells. 
 
After fifty six days of EtBr exposure, all the concentrations of EtBr tested caused a drastic 
decrease in the number of mitochondrial DNA copies (data not shown). From the three 
EtBr concentrations tested, 75 and 100 ng/ml caused the greatest decrease in mtDNA copy 
number (150 times less than the untreated cells). 
Oxygen consumption was then evaluated in cells cultured in the presence of EtBr for 64 
days (see also Figure 9) after 5 (Figure 25A), 12 (Figure 25B), 27 (Figure 25C) and 49 
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(Figure 25D) days following EtBr removal. Up to 27 days after EtBr removal, and for all 
the concentrations tested, oxygen consumption of EtBr-exposed cells was completely 
abolished, when compared to untreated cells. However, 49 days after EtBr removal, the 
cells that had been previously exposed to 50 and 100 ng/ml EtBr, completely recovered 
their oxygen consumption capacity. However, in cells exposed to 75 ng/ml EtBr, oxygen 
consumption remained low, compared to untreated cells. 
4 days without EtBr
0 50 75 100
0
50
100
150
ng/ml EtBr
O
x
y
g
e
n
 c
o
m
s
u
p
ti
o
n
(%
 o
f 
c
o
n
tr
o
l 
c
e
lls
)
12 days without  EtBr
0 50 75 100
0
50
100
150
ng/ml EtBr
O
x
y
g
e
n
 c
o
m
s
u
p
ti
o
n
(%
 o
f 
c
o
n
tr
o
l 
c
e
lls
)
27 days without  EtBr
0 50 75 100
0
50
100
150
ng/ml EtBr
O
x
y
g
e
n
 c
o
m
s
u
p
ti
o
n
(%
 o
f 
c
o
n
tr
o
l 
c
e
lls
)
49 days without  EtBr
0 50 75 100
0
50
100
150
ng/ml EtBr
O
x
y
g
e
n
 c
o
m
s
u
p
ti
o
n
(%
 o
f 
c
o
n
tr
o
l 
c
e
lls
)
A B
C D
 
Figure 25 - The presence of EtBr decreases lymphoblast oxygen consumption for at least 27 days. Lymphoblasts 
(cell line CTR 5724) were cultured in the absence (0 ng/ml EtBr) or in the presence of EtBr (50, 75 or 100 ng/ml) for 64 
days, and basal rate of O2 consumption was evaluated after 4 (A), 12  (B), 27 (C) and 49 days (D) upon EtBr removal. O2 
consumption was determined as described in Material and Methods. The presence of EtBr at any of the concentrations 
tested significantly decreased O2 consumption, for at least 27 days (A, B and C). Fourty nine days after EtBr removal (D) 
the cells exposed to 100 ng/ml EtBr totally recovered their respiration capacity. The cells exposed to 50 ng/ml EtBr 
recovered almost all of their respiration capacity, and the cells exposed to 75 ng/ml EtBr recovered about 50% of their 
respiration capacity. The control 100% corresponds to 11. 81 nmol O2/ml/min (A), 12.37 ± 1.85 nmol O2/ml/min (B), 
38.68 O2/ml/min (C) and 8.58 ± 1.19 nmol O2/ml/min (D). 
 
Next, we started a new experiment with 2 HD lines (5678 and 5610) and 2 CTR lines (4800 
and 4808) (Figure 9B). All cell lines were exposed to 0, 50 and 75 ng/ml of EtBr for 64 
days (Figure 26). Unfortunately, the HD 5610 cell line evidenced an extremely slow 
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proliferation rate, being therefore discontinued. The remaining cell lines did not present a 
significant reduction in oxygen consumption, 8 or 17 days after EtBr removal.  
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Figure 26  - Exposure to EtBr did not significantly reduce oxygen consumption in CTR 4800, CTR 4808 and HD 
5678 cell lines.. Lymphoblasts (cell lines CTR 4800, CTR 4808 and HD 5678) were cultured in the absence (0 ng/ml EtBr) 
or in the presence of EtBr (50, 75 ng/ml) for 64 days, and basal recording rate of O2 consumption was evaluated after 8 (A, 
C, E) and 17 days (B, D, F) upon EtBr removal. O2 consumption was measured as described in Material and Methods. 
The cell line CTR 4800 showed a decrease of about 50% in oxygen consumption after 8 days upon removal of both EtBr 
concentrations (A).  However, after 17 days, there was no difference between the cells exposed do EtBr and the untreated 
cells (B). The cell line CTR 4808 also showed little decrease in the oxygen consumption upon treatment (C and D). The 
same was observed in the cell line HD 5678 (E and F). The control 100% corresponds to 6.10 ± 0.8 nmol O2/ml/min/5 x 
106 cells (A), 4.71 ± 1.14 nmol O2/ml/min/5 x 10
6 cells (C), 4.86 ± 0.16 O2/ml/min/5 x 10
6 cells (E), 1.66 nmol 
O2/ml/min/5 x 10
6 cells (B), 13.59 nmol O2/ml/min/5 x 10
6 cells (D) and 3.83 nmol O2/ml/min/5 x 10
6 cells (F). 
6.2. DISCUSSION 
mHtt is widely expressed in the brain, but also in peripheral tissues (Sassone et al., 2009). 
Fibroblasts and lymphoblasts have been used as HD models for a long time (Menkes and 
Stein, 1973; Paul Imray and Kidson, 1983). Indeed, human HD lymphoblasts have 
provided important data about the mechanisms involved in the disease, such as genetic 
instability (Cannella et al., 2009), apoptotic cell death (Sawa et al., 1999; Costa et al., 2010), 
impaired mitochondrial Ca
2+
 buffering capacity (Panov et al., 2002), mitochondrial 
ultrastructural changes and altered mitochondrial membrane potential (Squitieri et al., 
2006). Our lab has previously demonstrated that lymphocytes obtained from peripheral 
blood of HD patients may reflect changes observed in HD brain, particularly the B type, 
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that showed increased Bax (pro-apoptotic protein) levels, and decreased mitochondrial 
membrane (Almeida et al., 2008). HD cybrids, in turn, provided an important model to 
study mitochondrial abnormalities (Kohan, 2004; Ferreira et al., 2011). In our lab, a model 
of HD cybrids is already available, which were made from a neuronal-like cell line with 
non-HD nucleus (NT-2 cell line) fused with mitochondria from HD patients‟ platelets. 
Indeed, these cybrid lines have provided important data about the bioenergetics deficits in 
HD models (Ferreira et al., 2011).  
In the present study we tried to optimize the conditions to generate rho-zero cell lines (cells 
depleted from mitochondrial DNA) (King and Attardi, 1989) from HD and CTR 
lymphoblasts, which may be important for revealing the important role of mitochondria in 
cells expressing mHtt. We used a method based on long-term cell culture with EtBr, a 
cationic and lipophilic agent that selectively damages mtDNA, inhibiting mtDNA 
replication and transcription, when present in low concentrations (King and Attardi, 1989). 
In this work, we performed two independent experiments with a total of 5 lymphoblastoid 
lines (2 HD and 3CTR). Results obtained with the first experiment suggested that 2 months 
(64 days) of exposure to 50, 75 or 100 ng/ml EtBr would be enough to bring these cells to a 
rho-zero status. Indeed, cells treated in these conditions showed extremely lower mtDNA 
copy number (data not shown), and also presented decreased proliferation rate, when 
compared to the untreated cells. This slowing of cell proliferation is an obvious 
consequence of mtDNA depletion, since the cells lack the mitochondria needed to produce 
ATP, and the glycolytic pathway seems not to be enough to compensate the decrease in 
OXPHOS system induced by mtDNA depletion (Piechota et al., 2006). Other authors have 
presented similar observations in different cell lines: 143B TK, treated for two months with 
50 ng/ml of EtBr (King and Attardi, 1989); HeLa cells, treated for 6 days with 50 ng/ml of 
EtBr (Piechota et al., 2006); human leukemia T-cell line cells (MOLT-4), treated for 26 
days with 50 ng/ml EtBr (Armand et al., 2004); and the human small airway epithelial 
(SAE) cell model, treated for two months with 50 ng/ml of EtBr (Huang et al., 2012). This 
deficit in cell proliferation, a probable consequence of metabolic alterations, was 
accompanied by a change in cell aggregation. Indeed, healthy cells tend to rapidly form 
large aggregates; so, the loss of this capacity observed in our study is in agreement with the 
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existence of some cellular changes in cells depleted of mtDNA. It is important to note that 
these observations were made before the end of EtBr exposure, meaning that a long 
exposure to EtBr is not needed in order to have cells with rho-zero characteristics. However, 
we noticed that after 35 days of exposure plus 25 days of EtBr removal, the cells were 
consuming oxygen to the same extent as was observed for untreated cells, meaning that, at 
that time, the cells are endowed with functional mitochondria. These observations suggest 
that cells need to be exposed to EtBr for a longer period, in order to decrease even more the 
number of functional mtDNA copies. After 64 days of EtBr exposure, we observed that the 
cells did not consume oxygen for, at least, 27 days after the EtBr removal. The lack of 
oxygen consumption suggests that the OXPHOS was not working properly because there 
were no functional mitochondria. However, the cells recovered their capacity to consume 
oxygen, after 49 days without EtBr. One possible explanation for this recovery (that 
probably corresponds to a recovery in the functional mtDNA) may be the fact that mtDNA 
defects are often heteroplasmic, and cells treated with EtBr may contain variable mixtures 
of defective and wild-type mtDNA or, alternatively, all cells within a population may not 
reach a rho-zero phenotype during EtBr treatment, since a few aerobically competent cells 
may survive in the cell culture (Miller et al., 1996). This increase in oxygen consumption 
was apparently not due to an increase in ROS production, since when we added KCN (an 
inhibitor of complex IV), the oxygen consumption was completely abolished, meaning that 
it was dependent on complex IV activity. Exposure to 100, 250 or 500 ng/ml of EtBr for 64 
days is not an alternative, since the cells tend to lose their capacity to properly proliferate. 
Eighty four days of 50 ng/ml of EtBr treatment largely decreased cells proliferation rate, in 
such a way that there were not enough cells to perform any further experiment (data not 
shown). 
Surprisingly, in the second set of experiments, even after 64 days of EtBr exposure, the 
cells did not lose their capacity to consume oxygen. This result suggests that an important 
amount of mitochondria in these cells maintained the capacity to consume oxygen, 
suggesting that the rho-zero state was not achieved. Again, the use of KCN at the end of 
every experiment proved that oxygen was consumed through the OXPHOS. Probably, the 
duration and concentration of EtBr exposure is  cell line-dependent, with different cells 
reacting differently to the same experimental conditions (King and Attardi, 1989). 
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In summary, in this work we were able to bring lymphoblast control cells to a rho-zero state 
for at least 27 days. However, the creation of rho-zero cell lines seemed to be dependent on 
the cell line, and further studies will be needed in order to define a precise protocol to 
create a rho-zero status from our lymphoblastoid cell lines. The main limitation seems to be 
a rapid mitochondrial repopulation, which presents some concerns to the maintenance of 
rho-zero status. 
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In conclusion, this work allowed us to better understand some of the HD pathologies that 
characterize the striatal cell model STHdh
Q111/Q111
 and, also, the positive effect that some 
compounds/proteins might have in this neurodegenerative disease, closely related to 
mitochondrial dysfunction. Here we showed that STHdh
Q111/Q111
 cells have higher ROS 
production, PCr and pyruvate levels, apoptosis and necrosis, and, on the other hand, lower 
cell viability, ATP/ADP ratio and lactate/pyruvate ratio. Also, we found a promising role of 
PDH in this HD model. Indeed, STHdh
Q111/Q111
 showed increased PDH phosphorylation/ 
inactivation and decreased enzyme activity and E1alpha protein levels. In agreement with 
these changes, we observed a protective effect of DCA, a compound that increases PDH 
activity, in ROS production and cell viability. Also, we observed decreased levels of LDH 
activity in mutant cells that were restored by 1 nM of IGF-1 (that slightly reduced the high 
levels of pyruvate, too). Any of the other bioenergetics changes were significantly affected 
by insulin or IGF-1. In addition, we demonstrated some interesting effects of iHDACs. 
Indeed, we observed that these compounds are able to increase mutant cell viability, 
decreasing cell death by apoptosis. In particular, SB (500 μM) was shown to be a promising 
compound, as it was able to decrease phosphorylation and increase the levels of the PDH 
E1alpha subunit in mutant cells. Lastly, we made important advancements in the 
establishment of a protocol for the creation of rho-zero cells. In fact, we were able to create 
and maintain those cells from lymphoblastoid cells for, at least, 27 days.  
So, herewith we took a step forward in the search for new therapeutic strategies in HD 
cellular pathology control, having iHDACs (namely SB) as the most promising 
neuroprotective agents. 
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